cycloserine profile

Cycloserine: Antibiotic substance produced by Streptomyces garyphalus. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6234
CHEMBL ID	771
CHEBI ID	40009
SCHEMBL ID	34322
MeSH ID	M0005492

Synonym
AC-4721
BIDD:GT0707
bdbm50038178
KBIO1_000098
DIVK1C_000098
sc-49088 ,
cicloserina [italian]
nsc 154851
cycloserinum [inn-latin]
3-isoxazolidinone, 4-amino-, (+)-
k-300
cicloserina [inn-spanish]
brn 0080798
oxamicina [italian]
einecs 200-688-4
miroserina
3-isoxazolidinone, 4-amino-, (r)-
d-4-amino-3-isossazolidone [italian]
i-1431
3-isoxazolidinone, 4-amino-, d-
r-4-amino-3-isoxazolidinone
EU-0100252
d-cycloserine, synthetic
SPECTRUM_000860
SPECTRUM5_000797
NCGC00016306-01
cas-68-41-7
NCGC00016306-02
lopac-c-7005
lopac-c-1159
NCGC00015213-01
NCGC00015213-03
cas-339-72-0
lopac-c-3909
NCGC00015213-02
DCS ,
r-(+)-cycloserine
(4r)-4-aminoisoxazolidin-3-one
d-amino-3-isoxazolidinone
(r)-3-isoxazolidinone, 4-amino-
nsc-76029
PRESTWICK3_001089
BSPBIO_001138
SMP1_000167
IDI1_000098
PRESTWICK2_001089
LOPAC0_000252
(r)-4-amino-isoxazolidin-3-one
micoserina
d-cs
pa-94
3-isoxazolidinone, 4-amino-, d
3-isoxazolidinone, 4-amino-, (+)- (8ci)
pa 94
drg-0195
ai3-50153
alpha-cycloserine
3-isoxazolidinone, 4-amino-, (r)
3-isoxazolidinone, 4-amino-, (4r)- (9ci)
(r)-4-amino-3-isoxazolidinone
closerin
(r)-(+)-cycloserine
e-733-a
closina
(r)-cycloserine
(4r)-4-amino-3-isoxazolidinone
hsdb 3218
(+)-4-amino-3-isoxazolidinone
AB00443920
MLS001423962
d-cycloserine
d-4-amino-3-isoxazolidinone
orientomycin
C08057
d-4-amino-3-isoxazolidone
cycloserine
seromycin
68-41-7
wasserina
tisomycin
farmiserina
novoserin
oxamycin
cyclo-d-serine
nsc-154851
cyclorin
miroseryn
d-oxamycin
(+)-cycloserine
cycloserin
tebemicina
d-cycloserine, powder
smr000058313
MLS000758215
DB00260
1PB9
cycloserine (jp17/usp/inn)
seromycin (tn)
D00877
CHEBI:40009 ,
cycloserinum
ro-1-9213
d-(+)-cycloserine
cicloserina
KBIO2_006476
KBIO2_003908
KBIOGR_000890
KBIOSS_001340
KBIO3_001341
KBIO2_001340
SPECTRUM3_000371
SPECTRUM2_000084
SPBIO_003029
SPBIO_000008
SPECTRUM4_000305
NINDS_000098
PRESTWICK1_001089
PRESTWICK0_001089
SPECTRUM1500215
BPBIO1_001252
BSPBIO_002121
NCGC00093713-01
NCGC00093713-02
C-9400 ,
C-9390 ,
d-cycloserine, >=96.0% (nt)
LMPK14000007
NCGC00016306-03
C 3909 ,
HMS2091I14
HMS2051C15
serine, cyclo-
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09 ,
r(+)-4-amino-3-isoxazolidinone
(r)-(+)-4-amino-3-isoxazolidinone
NCGC00016306-05
CHEMBL771 ,
HMS500E20
HMS1571I20
HMS1920C06
(4r)-4-amino-1,2-oxazolidin-3-one
A836140
(4r)-4-azaniumyl-4,5-dihydroisoxazol-3-olate;(r)-4-aminoisoxazolidin-3-one
HMS2098I20
HMS3260D06
HMS3259L19
nsc-756712
MLS002548887
pharmakon1600-01500215
cycloserine (d)
nsc756712
dtxcid902870
dtxsid8022870 ,
tox21_110361
d-cycloserine synth. bp 88
d-oxamicina
(r)-4-aminoisoxazolidin-3-one
HMS2232F03
AKOS015994626
CCG-39705
NCGC00016306-04
unii-95ik5ki84z
cycloserine [usp:inn:ban:jan]
4-27-00-05549 (beilstein handbook reference)
d-4-amino-3-isossazolidone
oxamicina
95ik5ki84z ,
NCGC00016306-07
LP00252
S1998
cycloserine [mi]
cycloserine [usp monograph]
cycloserine [who-dd]
cycloserine [hsdb]
cycloserine [inn]
cycloserine [who-ip]
cycloserinum [who-ip latin]
cycloserine [jan]
cycloserine [mart.]
cycloserine [usp impurity]
cycloserine [vandf]
cycloserine [orange book]
HY-B0030
NC00050
NC00676
SCHEMBL34322
tox21_110361_1
NCGC00016306-08
HS-0079
NCGC00260937-01
tox21_500252
3-isoxazolidinone, 4-amino-, (4r)-
4-amino-3-isoxazolidinone, d-
4-isoxazolidinamine, 3-oxo-, (d)-
nj-21
4-amino-3-isoxazolidinone, (r)-
cycloserine, pharmaceutical secondary standard; certified reference material
AB00443920_10
AB00443920_09
(r)-4-amino-3-isoxazolidone
bdbm50103516
F2173-1228
sr-01000759389
SR-01000759389-4
SR-01000075432-1
sr-01000075432
cycloserine, united states pharmacopeia (usp) reference standard
gtpl9489
SR-01000075432-2
SR-01000075432-10
SR-01000075432-5
SR-01000075432-9
SBI-0050240.P004
HMS3715I14
Q418508
EN300-97131
SDCCGSBI-0050240.P005
NCGC00016306-17
cycloserine-(d)
M01471
cycloserine, d(+)
d-cycloserine (standard)
HY-B0030R
CS-0695020
Z1198154206
cycloserine (usp monograph)
cycloserine (mart.)
cicloserina (inn-spanish)
cycloserine (usp:inn:ban:jan)
j04ab01
cycloserinum (inn-latin)
cycloserine (usp impurity)

Excerpt	Reference	Relevance
"D-cycloserine (DCS) is an anti-tuberculosis medication that has been utilized for years for drug-resistant tuberculosis. "	( D-Cycloserine-Induced Seizure Activity in the Emergency Department: A Case Report. Boykin, T; Kuhrau, S; Rech, MA, 2023)	2.35
"D-cycloserine (DCS) is a partial NMDA agonist that, along with lurasidone, is being investigated as a treatment for depression."	( NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models. Javitt, J; Jordan, W; Sapko, MT; Siegel, R, )	0.69
"D-cycloserine (D-CS) is a second-line antibiotic for TB that inhibits bacterial cell wall synthesis."	( Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model. Balaram, A; Conrad, WH; Dejneka, S; McMahon, M; Najibi, Z; Pawlowicz, P; Robbins, L, 2023)	1.75
"D-cycloserine is an antibiotic used for six decades without significant appearance and dissemination of antibiotic resistant strains, making it an ideal model compound to understand what drives resistance evasion."	( Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes. Cortes, T; Dagg, BM; de Carvalho, LPS; Evangelopoulos, D; Gutierrez, MG; Ho, MM; Khatri, B; Prosser, GA; Rodgers, A, 2019)	1.35
"d-Cycloserine (DCS) is a partial agonist of the glutamatergic N-methyl-d-aspartate (NMDA) receptor-associated glycine site, and it prevents the amnesic effects of the muscarinic receptor antagonist scopolamine in various memory tests in rodents. "	( d-Cycloserine reverses scopolamine-induced object and place memory deficits in a spontaneous recognition paradigm in rats. Ichitani, Y; Ozawa, T; Yamada, K, 2019)	1.96
"d-cycloserine is a broad-spectrum antibiotic that is currently being used as a secondary choice in the treatment of tuberculosis. "	( Determination of d-Cycloserine Impurities in Pharmaceutical Dosage Forms: Comparison of the International Pharmacopoeia HPLC-UV Method and the DOSY NMR Method. Časar, Z; Makuc, D; Naumoska, K; Plavec, J; Švab, Ž, 2020)	1.61
"D-cycloserine (DCS) is a D-Alanine analogue that targets peptidoglycan biosynthesis by inhibiting D-Alanine:D-Alanine ligase (Ddl)."	( Opposite effect of vancomycin and D-Cycloserine combination in both vancomycin resistant Staphylococcus aureus and enterococci. Boudrioua, A; Giraud, C; Hartke, A; Li, Y, 2020)	1.39
"D-Cycloserine is a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor. "	( Efficacy of adjunctive D-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Andrade, C; Kuppili, PP; Menon, V; Sarkar, S; Sathyanarayanan, G, 2021)	1.65
"D-cycloserine (DCS) is a partial N-methyl-D-aspartate receptor agonist that potentially augments response to exposure therapy in anxiety disorders by enhancing extinction learning. "	( No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. Cath, DC; Denys, DA; Duits, P; Hofmeijer-Sevink, MK; Hoogendoorn, AW; Rijkeboer, MM; van Balkom, AJ; van den Hout, MA; van Megen, HJ; Vulink, NC, 2017)	1.52
"d-Cycloserine is an important second-line drug used to treat MDR- and XDR-TB. "	( Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. Chen, J; Cui, P; Shi, W; Zhang, S; Zhang, W; Zhang, Y, 2017)	1.43
"D-cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes: alanine racemase and D-alanine:D-alanine ligase. "	( Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine. Batson, S; de Carvalho, LPS; de Chiara, C; Dowson, CG; Fishwick, CWG; Fülöp, V; Gobec, S; Lloyd, AJ; Majce, V; Rea, D; Roper, DI; Simmons, KJ; Thoroughgood, CW, 2017)	1.4
"Cycloserine (CYC) is a second line antitubercular drug that is used for the treatment of multidrug resistant tuberculosis (MDR-TB) along with other antitubercular agents and is often used in developing countries. "	( A selective and sensitive high performance liquid chromatography assay for the determination of cycloserine in human plasma. Hemanth Kumar, AK; Polisetty, AK; Ramachandran, G; Sudha, V; Vijayakumar, A, 2018)	2.14
"D-cycloserine (DCS) is a partial N-methyl-D-aspartate (NMDA) agonist that has attracted attention because of its cognitive enhancing properties, including in people with post-traumatic stress disorder (PTSD)."	( D-Cycloserine Facilitates Reversal in an Animal Model of Post-traumatic Stress Disorder. Abelson, JL; Floresco, SB; George, SA; Liberzon, I; Riley, J; Rodriguez-Santiago, M, 2018)	1.76
"d-Cycloserine is a second-line drug approved for use in the treatment of patients infected with Mycobacterium tuberculosis, the etiologic agent of tuberculosis. "	( Reinterpreting the mechanism of inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by D-cycloserine. de Carvalho, LP; Prosser, GA, 2013)	1.33
"d-Cycloserine is an effective second line antibiotic used as a last resort to treat multi (MDR)- and extensively (XDR) drug resistant strains of Mycobacterium tuberculosis . "	( Metabolomics analysis identifies d-Alanine-d-Alanine ligase as the primary lethal target of d-Cycloserine in mycobacteria. Barletta, RG; Fenton, RJ; Halouska, S; Marshall, DD; Powers, R; Zinniel, DK, 2014)	1.34
"D-Cycloserine (DCS) is an effective second-line drug against Mycobacterium tuberculosis (M."	( Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and menaquinone metabolic pathways? Chen, L; Hong, W; Xie, J, 2014)	1.21
"Cycloserine (CS) is a second-line anti-tuberculosis drug whose serum concentrations in tuberculosis (TB) patients are largely unknown."	( Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Bai, KJ; Chang, CC; Chang, JH; Chiang, CY; Chiang, YC; Chuang, HC; Hung, WY; Yu, MC, 2014)	1.43
"D-cycloserine (DCS) is a partial agonist of the glycine site coupled to the NMDA receptor (NMDAR). "	( D-cycloserine injected into the dorsolateral periaqueductal gray induces anxiolytic-like effects in rats. Gomes, FV; Guimarães, FS; Hott, SC; Kakihata, AM; Resstel, LB; Semedo, AC; Uliana, DL, 2014)	1.85
"D-Cycloserine is a glutamatergic N-methyl-d-aspartate receptor agonist that has been shown to facilitate the benefits of exposure therapy for anxiety disorders by enhancing the emotional learning in the exposures; therefore, we examined D-cycloserine-facilitation of exposure therapy to increase body mass index (BMI) in patients with anorexia nervosa."	( D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. Fewell, L; Kass, AE; Lenze, EJ; Levinson, CA; McCallum, K; Riley, EN; Rodebaugh, TL; Stark, L, 2015)	1.7
"D-cycloserine (DCS) is a cognitive enhancer that acts at the N-methyl-D-aspartate receptor to promote learning."	( D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Modi, ME; Young, LJ, 2011)	1.65
"D-Cycloserine appears to be an effective augmentation agent that enhances the effects of behavioral therapy in the treatment of anxiety disorders. "	( D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. Bloch, MH; Bontempo, A; Panza, KE, 2012)	1.82
"D-cycloserine (DCS) is an N-methyl-D-aspartate (NMDA) receptor partial agonist that facilitates extinction of conditioned fear in animals and cue exposure therapy (CET) for fear and anxiety disorders in people. "	( D-cycloserine effects on extinction of conditioned responses to drug-related cues. Carlezon, WA; Myers, KM, 2012)	1.82
"D-Cycloserine (DCS) is a partial NMDA receptor agonist that has been shown to enhance therapeutic response to exposure-based treatments for anxiety disorders, but has not been tested in the treatment of combat-related posttraumatic stress disorder (PTSD). "	( A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. Bryant, RA; Hermos, JA; Hofmann, SG; Litz, BT; Otto, MW; Salters-Pedneault, K; Steenkamp, MM, 2012)	1.36
"D-cycloserine (DCS) is a partial agonist at the NMDAR-associated glycine modulatory site that at high doses acts as a functional NMDAR antagonist."	( A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Bloch, B; Edelman, S; Gelfin, G; Heresco-Levy, U; Javitt, DC; Kremer, I; Levin, R, 2013)	1.21
"D-cycloserine (DCS) is an antibiotic that is currently used in second-line treatment of tuberculosis. "	( Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine. de Carvalho, LP; Prosser, GA, 2013)	1.32
"d-Cycloserine (DCS) is a broad-spectrum antibiotic that inhibits d-alanine ligase and alanine racemase activity. "	( Characterization of Escherichia coli D-cycloserine transport and resistant mutants. Baisa, G; Stabo, NJ; Welch, RA, 2013)	1.38
"l-Cycloserine (LCS) is an inhibitor of serine palmitoyltransferase (SPT), a rate-limiting enzyme for sphingolipid biosynthesis that is reported to show increased activity with development of the rat CNS."	( Effects of dietary sphingomyelin on central nervous system myelination in developing rats. Oshida, K; Shimizu, T; Takase, M; Tamura, Y; Yamashiro, Y, 2003)	0.88
"Cycloserine acts as a suicide inhibitor of alanine racemase and as such, serves as an antimicrobial agent."	( A side reaction of alanine racemase: transamination of cycloserine. Fenn, TD; Morollo, AA; Ringe, D; Stamper, GF, 2003)	1.29
"Cycloserine is a known alanine racemase suicide substrate, although its mechanism of inactivation is based on transaminase chemistry."	( Effect of a Y265F mutant on the transamination-based cycloserine inactivation of alanine racemase. Fenn, TD; Holyoak, T; Ringe, D; Stamper, GF, 2005)	1.3
"D-Cycloserine is an active site titrant of D-amino acid transaminase."	( Different modes of action of inhibitors of bacterial D-amino acid transaminase. A target enzyme for the design of new antibacterial agents. Manning, JM; Soper, TS, 1981)	0.82
"D-Cycloserine is a partial agonist of the strychnine-insensitive glycine site that inhibits the tonic hindlimb extension (THE) component of maximal electroshock seizures (MES). "	( Localization of an anatomic substrate for the anticonvulsant activity induced by D-cycloserine. Peterson, SL, )	1.08
"Cycloserine acts as a potent and selective modulator of the N-methyl-D- aspartate (NMDA) receptor-associated glycine recognition site, which may be a possible mechanism for this compound's positive effects on memory formation and retrieval processes in animals. "	( Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Herting, R; Knott, V; Mendis, T; Mohr, E; Sampson, M; Wesnes, K, 1995)	1.97
"D-Cycloserine (DCS) is a high-efficacy partial agonist at the strychnine-insensitive glycine modulatory site within the N-methyl-D-aspartate (NMDA)-receptor/ionophore complex. "	( Influence of D-cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice. Czuczwar, SJ; Roliński, Z; Wlaź, P, 1996)	1.37
"D-Cycloserine is an agonist at the N-methyl-D-aspartate (NMDA) subclass of glutamate receptor complex."	( D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Davis, RE; Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Rosse, RB, 1996)	1.57
"D-Cycloserine is an effective second-line drug against Mycobacterium avium and Mycobacterium tuberculosis. "	( Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. Barletta, RG; Cáceres, NE; Feng, Z; Harris, NB; Kapur, V; Wellehan, JF, 1997)	1.25
"D-cycloserine is a partial agonist on the glycine site of the N-methyl-D-aspartate glutamate receptor. "	( A preliminary study of D-cycloserine treatment in Alzheimer's disease. Falk, WE; Gunther, J; Tsai, GE, 1998)	1.32
"D-Cycloserine (DCS) is a peptidoglycan inhibitor. "	( Synergic activity of D-cycloserine and beta-chloro-D-alanine against Mycobacterium tuberculosis. David, S, 2001)	1.34
"D-Cycloserine is considered to be an efficient cognitive enhancer probably able to compensate for assumed loss of NMDA receptors during isolated rearing."	( Impaired visual memory in rats reared in isolation is reversed by D-cycloserine in the adult rat. Myhrer, T; Strømme Johannesen, T, 2002)	1.11
"D-Cycloserine is a partial agonist at the strychnine-insensitive neuronal glycine receptor and positively modulates the N-methyl-D-aspartate (NMDA) excitatory amino acid receptor. "	( Effects of NMDA modulation in scopolamine dementia. Jones, RW; Kirby, J; Wesnes, KA, 1991)	1
"D-Cycloserine is a broad-spectrum antibiotic used with other antibiotics to treat various forms of tuberculosis. "	( Simultaneous quantification of cycloserine and its prodrug acetylacetonylcycloserine in plasma and urine by high-performance liquid chromatography using ultraviolet absorbance and fluorescence after post-column derivatization. Bayne, WF; Gravellese, D; Hwang, SS; Maglietto, SM; Musson, DG, 1987)	1.28

Excerpt	Reference	Relevance
"D-Cycloserine (DCS) has previously been shown to facilitate fear extinction and decrease anxiety in animal and human studies."	( The role of microRNAs in the therapeutic action of D-cycloserine in a post-traumatic stress disorder animal model: an exploratory study. Daniels, WMU; Fairbairn, L; Gamieldien, J; Hart, S; Hemmings, SMJ; Jalali Sefid Dashti, M; Kidd, M; Malan-Müller, S; Seedat, S, 2017)	1.26
"D-Cycloserine has potential to enhance exposure therapy outcomes. "	( D-cycloserine-augmented one-session treatment of specific phobias in children and adolescents. Alston-Knox, C; Collings, N; Donovan, CL; Farrell, LJ; Garbharran, V; McConnell, H; Oar, EL; Ollendick, TH; Storch, EA; Testa, C; Tiralongo, E; Waters, AM; Zimmer-Gembeck, M, 2018)	1.92
"Cycloserine has been used previously in some areas of the world for the treatment of urinary tract infections. "	( Cycloserine as an alternative urinary tract infection therapy: susceptibilities of 500 urinary pathogens to standard and alternative therapy antimicrobials. Howe, R; Kugathasan, R; Wootton, M, 2014)	3.29
"d-Cycloserine (DCS) has been shown to enhance memory and, in a previous trial, once-weekly DCS improved negative symptoms in schizophrenia subjects. "	( d-Cycloserine augmentation of cognitive remediation in schizophrenia. Bello, I; Cain, CK; Creedon, T; Goff, DC; Laska, E; McCue, M; Tang, DI, 2014)	1.85
"D-cycloserine (DCS) has been shown to be effective in facilitating fear extinction in animal and human studies, however the precise mechanisms whereby the co-administration of DCS and behavioural fear extinction reduce fear are still unclear. "	( Molecular mechanisms of D-cycloserine in facilitating fear extinction: insights from RNAseq. Altorfer, M; Daniels, WM; Dashti, MJ; Fairbairn, L; Gamieldien, J; Hemmings, SM; Kidd, M; Malan-Müller, S; Oakeley, EJ; Seedat, S, 2016)	1.46
"d-cycloserine has the therapeutic properties of a desired medication for ASDs; specifically, a medication should not improve stereotypic behaviors at the expense of worsening sociability and vice versa."	( D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Benson, AD; Burket, JA; Deutsch, SI; Herndon, AL; Pepe, GJ; Winebarger, EE, 2012)	1.66
"D-cycloserine augmentation has the potential to increase the efficiency, palatability, and overall effectiveness of standard exposure therapy for OCD."	( D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Adson, D; Donahue, C; Foa, EB; Kim, SW; Kotlyar, M; Kushner, MG; McCabe, J; Peterson, J; Thuras, P, 2007)	1.78
"D-Cycloserine (DCS) has been shown to facilitate extinction of conditioned fear in rats and to improve fear reduction of social phobia and fear of heights in human studies. "	( Augmentation of fear extinction by D-cycloserine is blocked by proteasome inhibitors. Gean, PW; Lin, HC; Mao, SC, 2008)	1.34
"D-Cycloserine (DCS) has been reported to affect the central nervous system in man. "	( D-cycloserine enhances social behaviour in individually-housed mice in the resident-intruder test. McAllister, KH, 1994)	1.73
"D-Cycloserine has been shown to exert anticonvulsant activity in maximal electroshock seizures. "	( The anticonvulsant activity of D-cycloserine is specific for tonic convulsions. Peterson, SL; Schwade, ND, 1993)	1.29
"L-Cycloserine has been shown specifically to lower brain cerebroside levels in vivo, but the extent to which the decrease in whole brain cerebroside content reflects lower myelin cerebroside levels is not known since a substantial portion of cerebroside is found in nonmyelin membranes. "	( Cycloserine-induced decrease of cerebroside in myelin. Denisova, L; Miller, SL, 1998)	2.46
"D-Cycloserine has cognitive benefits for patients with Alzheimer's disease."	( Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Coyle, JT; Falk, WE; Gunther, J; Tsai, GE, 1999)	1.27
"D-cycloserine has been used for this purpose."	( D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Evenblij, CN; Kahn, RS; Maas, MF; van Berckel, BN; van der Geld, MA; van Loon, BJ; van Ree, JM; Wynne, HJ, 1999)	1.58
"D-Cycloserine has been studied for its ability to counteract the cognitive decrements produced by scopolamine in young and elderly healthy volunteers."	( Effects of NMDA modulation in scopolamine dementia. Jones, RW; Kirby, J; Wesnes, KA, 1991)	0.84

Excerpt	Reference	Relevance
"Cycloserine is thought to inhibit PLP-dependent enzymes by irreversibly forming a PMP-isoxazole."	( PMP-diketopiperazine adducts form at the active site of a PLP dependent enzyme involved in formycin biosynthesis. de Crécy-Lagard, V; Gao, S; Liu, H; Naismith, JH; Richards, NGJ; Zhu, W, 2019)	1.24
"D-cycloserine (DCS) promotes consolidation of extinction learning. "	( D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial. Bello, I; Cather, C; Dickerson, F; Diminich, ED; Goff, DC; Hart, KL; Kingdon, D; Li, C; Rakhshan Rouhakhtar, PJ; Troxel, AB, 2020)	2
"D-cycloserine did not increase the speed of motor learning or the overall amount learnt. "	( The NMDA receptor partial agonist d-cycloserine does not enhance motor learning. Favaron, E; Günthner, J; Harmer, CJ; Johansen-Berg, H; Reinecke, A; Scholl, J, 2016)	1.43
"D-Cycloserine can inhibit the growth of Mycobacterium tuberculosis and can be used as a second-line drug for the treatment of tuberculosis, especially for the use in developing countries."	( Original and efficient synthesis of D-cycloserine. Duan, H; Li, X; Meng, X; Qin, D; Wang, L; Wang, S; Zhang, Y, 2010)	1.19
"d-Cycloserine may enhance fear extinction. "	( Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. Nave, AM; Stevens, MC; Tolin, DF, 2012)	1.42
"D-cycloserine appears to enhance the benefits of exposure treatment when applied after a successful session, but it seems to have detrimental effects when administered after inadequate/unsuccessful exposure sessions."	( D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Hofmann, SG; Otto, MW; Pollack, MH; Powers, MB; Rosenfield, D; Smits, JA; Tart, CD; Telch, MJ, 2013)	1.83
"By Cycloserine a distinct increase of the GABA fluorescence is effected, presumably by inhibiting GABA-transaminase-activity."	( [Drug-induced influence of the GABA-fluorescence in rat brain structures with some comments on the chemistry of the reaction (author's transl)]. Görne, RC; Pfister, C, 1979)	0.77

Excerpt	Reference	Relevance
"D-cycloserine treatment selectively improved the performance in the extra-dimensional shift and the last reversal phase, where scopolamine effects were most pronounced."	( D-cycloserine rescues scopolamine-induced deficits in cognitive flexibility in rats measured by the attentional set-shifting task. Fendt, M; Siddik, MAB, 2022)	2
"D-cycloserine treatment resulted in significant improvements in numbing, avoidance, and anxiety symptoms; however, similar effects were also observed during placebo treatment."	( Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Blanaru, M; Cohen, T; Goichman, R; Heresco-Levy, U; Javitt, DC; Kremer, I; Reshef, A, 2002)	1.17
"D-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery."	( A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Herz, L; Posever, T; Schoenfeld, D; Shih, V; Tsai, G; Yovel, I; Zhang, H, 2005)	1.15
"L-Cycloserine treatment also was initiated neonatally to determine whether it would allow for a delayed BMT to have therapeutic value."	( Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Biswas, S; LeVine, SM, 2002)	0.87
"D-Cycloserine treatment was well tolerated and resulted in a significant reduction in negative symptoms (mean=15%). "	( Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Ermilov, M; Heresco-Levy, U; Javitt, DC; Shapira, B; Shimoni, J; Silipo, G, 2002)	1.32
"D-Cycloserine treatment of rel+ and relA strains caused a depletion of intracellular UDP-MurNAc-pentapeptide."	( Involvement of the relA gene product and feedback inhibition in the regulation of DUP-N-acetylmuramyl-peptide synthesis in Escherichia coli. Ishiguro, EE; Ramey, WD, 1978)	0.82

Excerpt	Reference	Relevance
"In this study, the anticonvulsant and adverse effects of compounds that belong to four different categories of systemically available N-methyl-D-aspartate (NMDA) receptor ligands were compared, namely the competitive antagonist CGP 40116, the noncompetitive antagonist MK-801 (dizocilpine), the glycineB receptor antagonist L-701,324, and the glycineB receptor high-efficacy partial agonist D-cycloserine."	( Anti-convulsant and adverse effects of the glycineB receptor ligands, D-cycloserine and L-701,324: comparison with competitive and non-competitive N-methyl-D-aspartate receptor antagonists. Wlaź, P, 1998)	0.7
" Adverse events associated with second-line drugs (SLDs) can have severe impact on efficient management."	( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016)	0.43
"To know the frequency of adverse events due to SLDs in patients of MDR-TB."	( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016)	0.43
" Adverse events associated with treatment were recognized primarily by clinical evidence and/or laboratory investigations that were advised at baseline and whenever clinically indicated during course of treatment."	( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016)	0.43
"119 adverse events were reported in 46 (46."	( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016)	0.43
"MDR-TB can be cured successfully with appropriate combination of drugs if adverse events associated with them can be managed aggressively and timely."	( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016)	0.43
"Few effective pharmacological treatment options exist for chronic back pain, the leading cause of disability in the US, and all are associated with significant adverse effects."	( A randomized placebo-controlled pilot study of the efficacy and safety of D-cycloserine in people with chronic back pain. Herrmann, K; Kaushal, G; Schnitzer, TJ; Torbey, S; Vania Apkarian, A; Yeasted, R, 2016)	0.66
" The characteristics of RMR-TB were compared with those with adverse events to rifampin (RAE-TB)."	( Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017)	0.46
"To assess the efficacy and adverse effects of D-cycloserine compared with placebo for social and communication skills in individuals with ASD."	( The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder. Aye, SZ; Mon, ST; Ni, H; Sein, HH; Wong, YKY; Zheng, Q, 2021)	1.14
" In addition, we contacted pharmaceutical companies, searched manufacturers' websites and sources of reports of adverse events."	( The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder. Aye, SZ; Mon, ST; Ni, H; Sein, HH; Wong, YKY; Zheng, Q, 2021)	0.88

Excerpt	Reference	Relevance
" The finding that motor impairing but not anticonvulsant effects of MK-801 were potentiated by D-cycloserine suggests that different pharmacodynamic actions of NMDA receptor antagonists are differentially modulated by the glycine receptor, which could be related to the regional heterogeneity of the NMDA receptor complex in the brain."	( Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. Baran, H; Löscher, W; Wlaź, P, 1994)	0.75
"To determine the effect of a high-fat meal, orange juice, and antacids on absorption of a single oral dose of cycloserine and to estimate its population pharmacokinetic parameters."	( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001)	0.85
" No other statistically significant differences were observed for Cmax and area under the curve from time zero to infinity across the four treatments."	( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001)	0.63
" The proposed method was found to be applicable to pharmacokinetic studies."	( A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for cycloserine in 50μL of human plasma: Its pharmacokinetic application. Gajula, R; Gandu, V; Maddela, R; Pilli, NR; Polagani, SR, 2013)	0.62
"A new generic formulation of cycloserine has been developed in China but the pharmacokinetic properties of cycloserine in the Chinese population have not been reported."	( Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study. Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zhou, H; Zhu, M, 2015)	0.97
" During the multiple-dose phase, blood samples were obtained before drug administration on Days 4, 5, and 6 to determine the Cmin at steady state."	( Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study. Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zhou, H; Zhu, M, 2015)	0.67
" The geometric mean (SD) Cmax value increased in proportion to cycloserine dose, from 19."	( Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study. Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zhou, H; Zhu, M, 2015)	0.91
"The pharmacokinetic properties of cycloserine were linear at doses from 250 mg to 1000 mg."	( Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study. Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zhou, H; Zhu, M, 2015)	0.95
" To evaluate the pharmacokinetic (PK) characteristics of clinically relevant, multidrug treatment regimens and to improve the feasibility of TDM, we conducted an open-label, multiple-dosing study with 16 healthy subjects who were divided into two groups."	( Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS, 2015)	0.42
" The method was successfully applied to a pharmacokinetic study of cycloserine in 30 healthy Chinese male subjects after oral administration of a single dose of cycloserine at 250, 500 and 750 mg under fasting conditions."	( A simplified LC-MS/MS method for rapid determination of cycloserine in small-volume human plasma using protein precipitation coupled with dilution techniques to overcome matrix effects and its application to a pharmacokinetic study. Di, X; Jin, J; Li, B; Liu, Y; Mao, Z; Wang, X; Xu, M, 2017)	0.94
"7), and peak concentration was 38."	( Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. Court, R; de Vries, N; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Stewart, A; Wiesner, L, 2018)	0.76
"We performed a systematic search to identify pharmacokinetic and pharmacodynamic studies performed with d-cycloserine."	( d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Alffenaar, JC; Banu, S; Chapagain, ML; Deshpande, D; Dheda, K; Foongladda, S; Gumbo, T; Heysell, SK; Houpt, ER; Koeuth, T; Köser, CU; Lee, PS; McIlleron, H; Mpagama, SG; Ogarkov, O; Pholwat, S; Schön, T; Simbar, N; Sturkenboom, MGG, 2018)	1.42
" It is important to generate pharmacokinetic studies of drugs used to treat MDR TB in children in different settings, which would provide useful information on the adequacy of drug doses."	( Pharmacokinetics of Second-Line Anti-Tubercular Drugs. Ramachandran, G, 2019)	0.51
" The method was successfully applied in a pharmacokinetic study for the determination of cycloserine in plasma of patients with drug-resistant tuberculosis."	( Sensitive Ultra-performance Liquid Chromatography Tandem Mass Spectrometry Method for Determination of Cycloserine in Plasma for a Pharmacokinetics Study. Mugabo, P; Mulubwa, M, 2019)	0.95

Excerpt	Reference	Relevance
"The in vitro activity of fludalanine ( MK641 ) combined with pentizidone ( MK642 ) so as to give a fludalanine /D-cycloserine ratio of 1:1 was compared with the activities of ampicillin, ticarcillin, cefuroxime, ceftazidime, and trimethoprim against 452 recent isolates and known beta-lactam- and trimethoprim-resistant strains."	( In vitro activity of fludalanine combined with pentizidone compared with those of other agents. Andrews, JM; Wise, R, 1984)	0.48
"It was demonstrated that glutoxim combination with second line drugs for tuberculosis treatment (cycloserine + rifabutine, cycloserine + protionamide) provided statistically significant decrease of intracellular mycobacteria growth in the murine lung tissue culture."	( [Effect of glutoxim in the combination with antitubercular agents of the second choice on the growth of drug resistant Mycobacteria tuberculosis in the cultured murine lung tissue]. Kunichan, AD; Perel'man, MI; Sokolova, GB, 2002)	0.53
"Based on preclinical studies showing that the partial N-methyl-D-aspartate (NMDA) agonist D-cycloserine (DCS) facilitates extinction of cocaine self-administration and cocaine-induced conditioned place preference, we evaluated whether 50 mg of DCS would reduce craving to cocaine cues when combined with cue exposure (CE) in cocaine dependent humans."	( D-cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence. Brady, KT; McRae-Clark, AL; Nietert, PJ; Prisciandaro, JJ; Saladin, ME; Santa Ana, EJ; Shaftman, SR, 2015)	1.36
" The CE protocol, consisting of repeated exposure to drug cues combined with skills training, resulted in extinction to cocaine cues as suggested by decreased craving within and between sessions in both treatment conditions."	( D-cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence. Brady, KT; McRae-Clark, AL; Nietert, PJ; Prisciandaro, JJ; Saladin, ME; Santa Ana, EJ; Shaftman, SR, 2015)	1.14

Excerpt	Reference	Relevance
" The bile salts are important surfactants in man, and modify the absorption rate of tetracycline, but not of doxycycline, sulphadimidine and cycloserine."	( Drug absorption in patients with T-tube after cholecystectomy. Aukee, S; Jussila, J; Karjalainen, P; Venho, VM, 1975)	0.46
"In a previous study we have shown that cultured epithelial cell lines can be used to measure the transepithelial passage of antimicrobial agents across the intestine and to obtain information on the mechanisms of transport utilized and predict the bioavailability of the antimicrobial agents after oral administration."	( D-cycloserine uses an active transport mechanism in the human intestinal cell line Caco 2. Islam, K; Ranaldi, G; Sambuy, Y, 1994)	1.01
" The central bioavailability of peripherally administered glycine has not been adequately characterized in humans."	( IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Abi-Saab, D; Bennett, A; Cassello, K; Charney, DS; D'Souza, DC; Gil, R; Karper, LP; Krystal, JH; Morrissey, K; Sturwold, R; White, J; Zuzarte, E, 2000)	0.62
" This study was conducted to explore issues relating to bioavailability in the presence of food, orange juice, and antacid."	( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004)	0.32
" The pharmacokinetics of clofazimine were assessed using individual- and population-based methods and relative bioavailability compared to fasting administration was determined."	( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004)	0.32
"Administration of clofazimine with a high fat meal provides the greatest bioavailability, however, bioavailability is associated with high inter- and intra-subject variability."	( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004)	0.32
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Basing their comment on the published literature, they analyze the properties, pharmacology, toxicity, and side-effects of each medication, and define their dosage and modes of administration."	( [Principles underlying the use of antituberculosis medication in children (author's transl)]. Besson-Leaud, M; Ollivier, A, )	0.13
" Parenteral injections of D-cycloserine produced a biphasic dose-response curve which suggested partial agonism."	( Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Cler, JA; Emmett, MR; Iyengar, S; Mick, SJ; Rao, TS; Wood, PL, 1991)	0.94
" Stimulation of binding induced by DCS in the presence of fixed concentrations of glycine resulted in a family of dose-response curves, consistent with the antibiotic having the property of a partial agonist at this glycine site."	( D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Bowen, DM; Chessell, IP; Francis, PT; Procter, AW, 1991)	1
" Moreover, the stimulation of [3H]TCP binding induced by D-cycloserine in the presence of various fixed concentrations of glycine results in a family of dose-response curves which asymptotically converge to 40-50% of the maximal stimulation induced by glycine alone."	( D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Compton, RP; Hood, WF; Monahan, JB, 1989)	1.24
" The procedure is sufficiently sensitive, precise, and accurate for the determination of cycloserine in its dosage form."	( Spectrophotometric determination of cycloserine with 9-methoxyacridine. Stewart, JT; Yoo, GS, 1988)	0.77
") facilitated DNMS performance significantly with an inverted U-shaped dose-response curve when given 30 min before testing."	( D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys. Aigner, TG; Matsuoka, N, 1996)	1.02
" However, multiple dosing with either ACPC or DCS (6 daily doses, 200 mg/kg) produced an apparent behavioral adaptation, as the immobility data were indistinguishable from chronic saline administration."	( Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Boje, KM; Lopes, T; Neubauer, P, 1997)	0.3
"05) prevented the increase in the percentage of open-arm entries and the time spent in the open arms of elevated plus-maze test induced by ethanol, exhibiting a U-shaped dose-response curve."	( D-cycloserine blocks the effects of ethanol and HA-966 in rats tested in the elevated plus-maze. Moraes Ferreira, VM; Morato, GS, 1997)	1.02
" Dose-response curves were right-shifted by aging (twice the dose was required to achieve the same enhancement compared with controls)."	( Age- and dose-dependent facilitation of associative eyeblink conditioning by D-cycloserine in rabbits. Disterhoft, JF; Thompson, LT, 1997)	0.52
" Higher medication dosage or long-term treatment may be required."	( A preliminary study of D-cycloserine treatment in Alzheimer's disease. Falk, WE; Gunther, J; Tsai, GE, 1998)	0.6
" CS is significantly removed by hemodialysis and should be dosed after hemodialysis."	( The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Childs, JM; Fish, DN; Malone, RS; Peloquin, CA; Spiegel, DM, 1999)	0.59
" The three doses of DCS reduced this increase significantly and resulted in a U-shaped dose-response curve, where 15 mg/kg had a stronger compensatory effect than both 5 and 50 mg/kg."	( Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Andersen, JM; Lindberg, V; Myhrer, T, 2002)	0.61
" Subcutaneous DCS injection before or after extinction training significantly enhanced extinction, and the dose-response curve for this effect was linear."	( Effects of D-cycloserine on extinction of conditioned freezing. Cranney, J; Ledgerwood, L; Richardson, R, 2003)	0.69
"These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology."	( Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Anderson, P; Davis, M; Graap, K; Hodges, L; Ressler, KJ; Rothbaum, BO; Tannenbaum, L; Zimand, E, 2004)	0.57
"The pilot data provide preliminary support for the use of short-term dosing of d-cycloserine as an adjunctive intervention to exposure therapy for SAD."	( Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Eisenmenger, K; Hofmann, SG; Meuret, AE; Otto, MW; Pollack, MH; Shiekh, M; Simon, NM; Smits, JA, 2006)	0.83
" The review of the literature provides preliminary support for the use of acute dosing of DCS as an adjunctive intervention to exposure therapy for anxiety disorders, including specific phobia and social anxiety disorder."	( Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. Hofmann, SG; Otto, MW; Pollack, MH, )	0.37
" The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time."	( Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences. Barrera, L; de Kantor, IN, 2007)	0.34
"Daily dosing with d-cycloserine has inconsistently improved negative symptoms in schizophrenia patients, whereas intermittent dosing significantly facilitated exposure-based therapy in two studies of patients with phobic anxiety."	( Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Cather, C; Evins, AE; Goff, DC; Gottlieb, JD; Green, MF; Otto, MW; Raeke, L; Schoenfeld, D; Walsh, J, 2008)	1.03
"Once-weekly dosing with d-cycloserine for 8 weeks produced persistent improvement of negative symptoms compared to placebo, although statistical significance was, in part, the result of worsening of negative symptoms with placebo."	( Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Cather, C; Evins, AE; Goff, DC; Gottlieb, JD; Green, MF; Otto, MW; Raeke, L; Schoenfeld, D; Walsh, J, 2008)	1.01
" Therapy was performed according to regimens 3 and 1, by using individual dosage regimens depending on the extent and severity of a specific process, the presence of complications, and age-related features."	( [Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis]. Dovgaliuk, IF; Ovchinnikova, IuE; Starshinova, AA, 2009)	0.35
" Present findings therefore confirm the intrinsic anxiolytic activity of DCS in untrained animals, with the observed bell-shaped dose-response function most probably indicative of varying affinities and intrinsic activities at NMDA receptor subtypes."	( Anxioselective profile of glycineB receptor partial agonist, D-cycloserine, in plus-maze-naïve but not plus-maze-experienced mice. Howard, K; Rodgers, RJ; Stewart, S; Waring, P; Wright, FL, 2010)	0.6
" Likewise, a similar dosing regimen of sarcosine or D-serine did not cause evident activity-impairing effect."	( D-cycloserine, sarcosine and D-serine diminish the expression of cocaine-induced conditioned place preference. Chang, WT; Cheng, LY; Cherng, CG; Chuang, JY; Kao, GS; Lee, YS; Yang, FY; Yu, L, 2013)	1.11
" Once-weekly dosing of D-cycloserine produces persistent improvement when combined with cognitive behavioral therapy (CBT) in anxiety disorders."	( D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Cather, C; Creedon, T; Goff, DC; Gottlieb, JD; Macklin, EA; Shanahan, M, 2011)	1.39
" Subgroup analysis and meta-regression were used to examine the effects of D-cycloserine dosage and timing (relative to exposure therapy), diagnostic indication, number of therapy sessions, and trial methodological quality on D-cycloserine efficacy."	( D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. Bloch, MH; Bontempo, A; Panza, KE, 2012)	1.33
" In contrast to a previous meta-analysis that examined D-cycloserine's effects in both animals and humans, we found no evidence of an effect of dose number, dose timing, or dosage of D-cycloserine on reported efficacy in the ranges studied."	( D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. Bloch, MH; Bontempo, A; Panza, KE, 2012)	1.35
" We will describe the memory enhancing properties of DCS, review findings from randomized controlled studies of DCS in anxious populations and discuss mechanism, dosing and timing issues."	( D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Asnaani, A; Hofmann, SG; Sawyer, AT, 2012)	1.1
"For the purposes of this study, no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3, which measures stereotypies/repetitive movements."	( A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Deutsch, SI; Hartmann, K; Herndon, A; Manser, P; Okwara, L; Urbano, M, )	0.5
" d-Cycloserine, a partial glycine agonist at the N-methyl-d-aspartic acid receptor, was tested in a double-blind randomized trial in 20 older adolescents and young adults with autism spectrum disorders using two dosing strategies (50 mg daily versus 50 mg weekly) for 8 weeks with a 2-week follow-up after discontinuation."	( A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. Deutsch, SI; Hartmann, K; Manser, P; Okwara, L; Urbano, M, 2015)	1.41
"Our result suggested that with the careful optimization of DCS-augmented ERP therapy by fine-tuning timing and dosing of DCS administration and number and frequency of ERP sessions, DCS may enhance the efficacy of ERP therapy in reducing the symptomatic severity of OCD patients, especially at early stage of the treatment; therefore, DCS augmentation could possibly reduce treatment cost, reduce treatment drop and refusal rate, and help to improve access to the limited number of experienced therapists."	( D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis. Du, Y; Han, J; Liu, G; Wang, X; Xia, J, 2015)	1.14
"Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs would allow for optimal individualized dosage adjustments and improve drug safety and therapeutic outcomes."	( Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS, 2015)	0.42
" In this review, we evaluate its therapeutic potential in neuropsychological disorders and discuss its pitfalls in terms of dosing and application frequency as well as its safety in low-dose therapy."	( D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. Paulus, W; Schade, S, 2016)	1.16
"Studies in animals and clinical trials in patients with anxiety disorders have demonstrated that single or intermittent dosing with DCS enhances memory consolidation."	( D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity. Goff, DC, 2017)	1.18
" Early trials have demonstrated benefit with intermittent DCS dosing for negative symptoms and memory."	( The Therapeutic Role of d-Cycloserine in Schizophrenia. Goff, D, 2016)	0.73
" We also performed simulations to provide insight into optimizing the dosing of cycloserine."	( Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis. Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA; Schmidt, S, 2019)	2.18
" We also investigated the association between DCS administration characteristics and treatment outcome to find optimal dosing parameters."	( Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. Altemus, M; Anderson, P; Andersson, E; Cukor, J; Davis, M; de Kleine, RA; de la Cruz, LF; Difede, J; Dunlop, BW; Farrell, LJ; Finck, C; Frumento, P; Geffken, GR; Geller, D; Gerardi, M; Golfels, F; Goodman, WK; Guastella, AJ; Gutner, CA; Hendriks, GJ; Heyman, I; Hofmann, SG; Jovanovic, T; Kushner, MG; Lee, FS; Lenze, EJ; Levinson, CA; Lewin, AB; Mataix-Cols, D; McConnell, H; McNamara, JP; Monzani, B; Murphy, TK; Norrholm, S; Otto, MW; Pérez-Vigil, A; Plag, J; Pollack, MH; Ressler, KJ; Rodebaugh, TL; Rosenfield, D; Rothbaum, BO; Rück, C; Smits, JAJ; Storch, EA; Ströhle, A; Tart, CD; Thuras, P; Tolin, DF; Turner, C; van Minnen, A; Waters, AM; Weems, CF; Wilhelm, S; Wyka, K, 2019)	0.78
" Therefore, we introduced the DOSY (diffusion ordered spectroscopy) NMR (nuclear magnetic resonance) technique to determine the levels of d-cycloserine impurities in pharmaceutical dosage forms."	( Determination of d-Cycloserine Impurities in Pharmaceutical Dosage Forms: Comparison of the International Pharmacopoeia HPLC-UV Method and the DOSY NMR Method. Časar, Z; Makuc, D; Naumoska, K; Plavec, J; Švab, Ž, 2020)	1.09
" These findings have prompted investigation of DCS dosing tailored to results of exposure sessions."	( Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. Andrews, L; Carpenter, J; Conroy, K; Curtiss, J; Dowd, S; Dutcher, CD; Hofmann, SG; Kind, S; Lewis, EM; Otto, MW; Papini, S; Pollack, MH; Rosenfield, D; Smits, JAJ; Witcraft, SM, 2020)	0.9
" The results showed that d-cycloserine, a partial glycine agonist, was well tolerated, the 2 dosing strategies did not differ, and improvement was noted on the "lethargy/social withdrawal" and "stereotypic behavior" subscales of the Aberrant Behavior Checklist."	( From Mouse to Man: N-Methyl-d-Aspartic Acid Receptor Activation as a Promising Pharmacotherapeutic Strategy for Autism Spectrum Disorders. Burket, JA; Deutsch, SI, 2023)	1.21

Role	Description
antitubercular agent	A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
antimetabolite	A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
NMDA receptor agonist	An excitatory amino acid agonist which binds to NMDA receptors and triggers a response.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organooxygen heterocyclic antibiotic
organonitrogen heterocyclic antibiotic
4-amino-1,2-oxazolidin-3-one	A member of the class of oxazolidines that is isoxazoldin-3-one which is substituted at position 4 by an amino group.
zwitterion	A neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	39.8107	0.0251	20.2376	39.8107	AID886
Chain B, HADH2 protein	Homo sapiens (human)	Potency	39.8107	0.0251	20.2376	39.8107	AID886
acetylcholinesterase	Homo sapiens (human)	Potency	0.8709	0.0025	41.7960	15,848.9004	AID1347398
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	7.4978	0.0060	38.0041	19,952.5996	AID1159521
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	1.5849	0.0013	7.7625	44.6684	AID914; AID915
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	3.9811	0.0013	18.0743	39.8107	AID926; AID938
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	0.5323	0.5318	15.4358	37.6858	AID504845
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	38.9018	0.0123	7.9835	43.2770	AID1645841
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	23.4105	0.0010	24.5048	61.6448	AID743212; AID743215
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	25.0467	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	18.8336	0.0017	23.8393	78.1014	AID743083
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	50.1187	0.5406	17.6392	96.1227	AID2364; AID2528
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	39.8107	0.0063	6.9043	39.8107	AID883
chromobox protein homolog 1	Homo sapiens (human)	Potency	8.4368	0.0060	26.1688	89.1251	AID488953
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	23.7101	0.0003	23.4451	159.6830	AID743065
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	5.0119	0.0398	16.7842	39.8107	AID1454
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	14.1254	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	21.4587	0.0316	10.2792	39.8107	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	44.6684	0.1778	24.7352	79.4328	AID488949
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	28.1838	0.0010	6.0009	35.4813	AID943
lamin isoform A-delta10	Homo sapiens (human)	Potency	6.3096	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	39.8107	0.0063	8.2350	39.8107	AID883
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	21.4587	1.0000	12.2248	31.6228	AID885
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	33.8078	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, N-methyl-D-aspartate Receptor Subunit 1	Rattus norvegicus (Norway rat)	Ki	241.0000	0.5400	82.8533	241.0000	AID977610
Chain A, N-methyl-D-aspartate Receptor Subunit 1	Rattus norvegicus (Norway rat)	Ki	241.0000	0.5400	82.8533	241.0000	AID977610
Chain A, N-methyl-D-aspartate Receptor Subunit 1	Rattus norvegicus (Norway rat)	Ki	241.0000	0.5400	82.8533	241.0000	AID977610
Bile salt export pump	Rattus norvegicus (Norway rat)	IC50 (µMol)	1,000.0000	0.4000	2.7500	8.6000	AID1209456
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.1100	7.1903	10.0000	AID1209455; AID1449628
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	4.8350	0.0007	1.6003	10.0000	AID143065; AID145260
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3000	0.0007	1.6306	10.0000	AID145260
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3000	0.0006	1.5257	10.0000	AID145260
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3000	0.0007	1.7472	10.0000	AID145260
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3000	0.0007	1.7411	10.0000	AID145260
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3000	0.0007	1.7411	10.0000	AID145260
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3000	0.0007	1.7411	10.0000	AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.9500	0.0030	1.2903	8.3000	AID145252
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.9500	0.0030	1.0222	6.8600	AID145252
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.9500	0.0030	0.8669	6.8600	AID145252
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	EC50 (µMol)	10.5250	0.0030	1.1127	6.8600	AID143225; AID145252
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.9500	0.0030	1.3937	8.3000	AID145252
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.9500	0.0030	0.9051	6.8600	AID145252
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.9500	0.0030	0.9051	6.8600	AID145252
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
monoatomic ion transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
amino acid transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
taurine transmembrane transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
proline transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
alanine transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
amino acid import across plasma membrane	Proton-coupled amino acid transporter 1	Homo sapiens (human)
glycine transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
proline transmembrane transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
proton transmembrane transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
L-alanine transport	Proton-coupled amino acid transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
amino acid:proton symporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
proline:proton symporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
taurine transmembrane transporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
protein binding	Proton-coupled amino acid transporter 1	Homo sapiens (human)
amino acid transmembrane transporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
alanine transmembrane transporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
L-alanine transmembrane transporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
L-proline transmembrane transporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
glycine transmembrane transporter activity	Proton-coupled amino acid transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
lysosomal membrane	Proton-coupled amino acid transporter 1	Homo sapiens (human)
endoplasmic reticulum	Proton-coupled amino acid transporter 1	Homo sapiens (human)
plasma membrane	Proton-coupled amino acid transporter 1	Homo sapiens (human)
apical plasma membrane	Proton-coupled amino acid transporter 1	Homo sapiens (human)
vacuolar membrane	Proton-coupled amino acid transporter 1	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID630741	Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21	Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID1071104	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID774298	Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis ATCC 35838	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID1584836	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 to 24 hrs by microdilution assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
AID1294351	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by BacTiter-Glo cell viability assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
AID1584826	Inhibition of full-length 6His-tagged Mycobacterium tuberculosis H37Rv Ddl expressed in Escherichia coli BL21(DE3)pLysS by UV-Vis spectrophotometric analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
AID1188166	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by microdilution AlamarBlue broth assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Sequential synthesis of amino-1,4-naphthoquinone-appended triazoles and triazole-chromene hybrids and their antimycobacterial evaluation.
AID571076	Antimicrobial activity against Enterococcus faecium OC3312 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID143065	In vitro inhibitory activity to inhibit [3H]glycine binding to NMDA receptor	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
AID530543	Induction of PtcaA::lacZ gene expression in Staphylococcus aureus SH1000 at 150 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.
AID428964	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL OC3726 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID55425	Antibacterial activity against D-alanyl-D-alanine ligase from Streptococcus faecalis (ATCC 8043)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID671431	Antimycobacterial activity against Mycobacterium bovis BCG assessed as inhibition of microbial growth at 0.5 to 100 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID1501383	Inhibition of cell wall biosynthesis in Bacillus subtilis assessed as induction of formation of misshapen cells at 37.5 ug/ml incubated for 2 hrs by FM-4-64 staining based assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Arylthiazole antibiotics targeting intracellular methicillin-resistant Staphylococcus aureus (MRSA) that interfere with bacterial cell wall synthesis.
AID1071118	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 50 ug/ml after 7 days by microplate Alamar blue assay relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID1713722	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth by microdilution alamar blue broth assay	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities.
AID571289	Inhibition of LPS-deficient Escherichia coli OC2530 MurF assessed as UDP-MurNAc-pentapeptide product level at 2 times MIC by HPLC (Rvb = 1 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497909	Inhibition of IPTG-stimulated Escherichia coli K-12 envA at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID409603	Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes at 20 uM	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Identification of aquaporin 4 inhibitors using in vitro and in silico methods.
AID1072948	Inhibition of alanine racemase in Mycobacterium tuberculosis H37Rv at 5 times MIC preincubated for 16 hrs followed by compound re-addition with L-Ala-[13C]-[3H] measured over 8 hrs by LC-MS/MS analysis	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID285161	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID571277	Bacteriostatic activity against Staphylococcus aureus ATCC 29213 at 2 times MIC	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID774296	Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis ATCC 35820	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID52925	Minimum inhibitory concentration compared to D-cycloserine, against Citrobacter freundii 55.13	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID571074	Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID430785	Partial agonist activity at glycine site of NMDA receptor in rat brain cortex membrane assessed as potentiation of [3H]Mk-801 binding by liquid scintillation counting	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
AID127623	The compound was tested for urinary recovery was assayed for its content of free cycloserine by employing the bioassay in mouse	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Use of acetylacetone to prepare a prodrug of cycloserine.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID64589	Minimum inhibitory concentration compared to D-cycloserine, against Escherichia coli DC2	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID428963	Antibacterial activity against Enterococcus faecium OC3312 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1467546	Antimicrobial activity against Mycobacterium tuberculosis H37Rv by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14	One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE.
AID571075	Antimicrobial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID560781	Antibacterial activity against Staphylococcus aureus TS10007 harboring ddlA Asp39Asn mutation in fifth-instar silkworm larva infection model assessed as compound concentration per gram of larva causing reduction in survival after 48 hrs post dose at 27 de	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID1765763	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of bacterial growth at 5 ug/ml measured by microplate alamar blue assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Design and synthesis of novel 5-alkynyl pyrimidine nucleosides derivatives: Influence of C-6-substituent on antituberculosis activity.
AID68443	antibacterial activity was reported as zones of inhibition in the disk diffusion assay using Escherichia coli	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Use of acetylacetone to prepare a prodrug of cycloserine.
AID671440	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 10 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID497906	Inhibition of IPTG-stimulated Escherichia coli K-12 ddlB at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID543953	Antibacterial activity against tetracycline-resistant Staphylococcus aureus COL-S carrying SSpbpD plasmid	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID560777	Antibacterial activity against Staphylococcus aureus TS2921 harboring ddlA Asp102Asn mutation in presence of 100 mM D-Ala-D-Ala, which complements temperature sensitivity after 20 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID55413	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Escherichia coli Tem 2+ 4351	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID163731	Minimum inhibitory concentration compared to D-cycloserine, against providencia alcalifaciens 58.62	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID55427	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Streptococcus faecalis 2864	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID428962	Antibacterial activity against Enterococcus faecalis ATCC 29212 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID497908	Inhibition of IPTG-stimulated Escherichia coli K-12 ftsA at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID640329	Antimycobacterial activity against Mycobacterium bovis BCG assessed as growth inhibition at 100 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID499896	Antitubercular activity against Mycobacterium bovis BCG after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID1602935	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 3 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID560772	Antibacterial activity against Staphylococcus aureus RN4220 after 20 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID428968	Antibacterial activity against LPS-deffective Escherichia coli OC2530 by CLSI broth microdilution method in presence of permeabilizer polymyxin B nonapeptide	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID432805	Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL at 42 degC by population analysis method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Role of a sodium-dependent symporter homologue in the thermosensitivity of beta-lactam antibiotic resistance and cell wall composition in Staphylococcus aureus.
AID1765753	Antimycobacterial activity against Mycobacterium bovis BCG assessed as inhibition of bacterial growth at 10 ug/ml measured by microplate alamar blue assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Design and synthesis of novel 5-alkynyl pyrimidine nucleosides derivatives: Influence of C-6-substituent on antituberculosis activity.
AID1071659	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by Alamar Blue staining-based broth microdilution assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Antimycobacterial evaluation of novel hybrid arylidene thiazolidine-2,4-diones.
AID1072946	Drug metabolism in Mycobacterium tuberculosis H37Rv assessed as compound remaining at 0.25 to 5 times MIC for 16 hrs measured 15 to 60 mins post compound washout	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID571071	Antimicrobial activity against LPS-deffective Escherichia coli OC2530 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID530746	Induction of PlytR::lacZ gene expression in Staphylococcus aureus SH1000 at 150 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.
AID428961	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID428956	Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1765755	Antimycobacterial activity against Mycobacterium bovis BCG assessed as inhibition of bacterial growth at 5 ug/ml measured by microplate alamar blue assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Design and synthesis of novel 5-alkynyl pyrimidine nucleosides derivatives: Influence of C-6-substituent on antituberculosis activity.
AID428970	Antibacterial activity against Escherichia coli NovaBlue by CLSI broth microdilution method in presence of permeabilizer polymyxin B nonapeptide	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID640337	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as growth inhibition at 10 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID671449	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID203158	Minimum inhibitory concentration compared to D-cycloserine, against Serratia marcescens A 174	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID428969	Antibacterial activity against Escherichia coli ATCC 25922 by CLSI broth microdilution method in presence of permeabilizer polymyxin B nonapeptide	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID733062	Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution alamar Blue broth assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
AID430787	Antagonist activity at glycine site of NMDA receptor in rat brain cortex membrane assessed as inhibition of [3H]Mk-801 binding by liquid scintillation counting in presence of maximally active glycine	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
AID497737	Inhibition of IPTG-stimulated Escherichia coli K-12 ftsA at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID571296	Inhibition of LPS-deficient Escherichia coli OC2530 MurF harboring pASK plasmid assessed as UDP-MurNAc-pentapeptide product level at 2 times MIC by HPLC (Rvb =880 +/- 17 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID497722	Inhibition of IPTG-stimulated Escherichia coli K-12 ftsA at 16 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497738	Inhibition of IPTG-stimulated Escherichia coli K-12 yadR at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1071117	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 25 ug/ml after 7 days by microplate Alamar blue assay relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID530755	Induction of PsgtB::lacZ gene expression in Staphylococcus aureus SH1000 at 150 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.
AID1664585	Antitubercular activity against Mycobacterium bovis BCG assessed as bacterial growth inhibition at 5 ug/ml by MABA relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1401966	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis and antimycobacterial activity of triterpeni≿ A-ring azepanes.
AID560780	Antibacterial activity against Staphylococcus aureus TS5337 harboring ddlA Pro178Ser mutation in fifth-instar silkworm larva infection model assessed as compound concentration per gram of larva causing reduction in survival after 48 hrs post dose at 27 de	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID479637	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 5 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.
AID93891	Minimum inhibitory concentration compared to D-cycloserine, against Klebsiella pneumoniae 53.153	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID499906	Antitubercular activity against Mycobacterium tuberculosis H37Ra infected in BALB/c mouse assessed as reduction of CFU counts in spleen at 50 mg/kg, ip administered 5 days after infection for 25 days measured after 3 days last dose	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID574806	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID306279	Inhibition of Escherichia coli DdlB	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl).
AID1765761	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of bacterial growth at 10 ug/ml measured by microplate alamar blue assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Design and synthesis of novel 5-alkynyl pyrimidine nucleosides derivatives: Influence of C-6-substituent on antituberculosis activity.
AID640332	Antimycobacterial activity against Mycobacterium bovis BCG assessed as growth inhibition at 1 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID571282	Inhibition of LPS-deficient Escherichia coli OC2530 MurF assessed as UDP-MurNAc-tripeptide substrate level at 2 times MIC by HPLC (Rvb = 1 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1071119	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 100 ug/ml after 7 days by microplate Alamar blue assay relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID560779	Antibacterial activity against Staphylococcus aureus TS2921 harboring ddlA Asp102Asn mutation in fifth-instar silkworm larva infection model assessed as compound concentration per gram of larva causing reduction in survival after 48 hrs post dose at 27 de	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID428967	Antibacterial activity against Escherichia coli NovaBlue by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID145252	In vitro concentration eliciting half-maximal effect on [3H]-MK 801 radioligand binding to NMDA receptor	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
AID499893	Antitubercular activity against Mycobacterium bovis BCG at 5 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID1072949	Inhibition of D-alanine-D-alanine ligase in Mycobacterium tuberculosis H37Rv assessed as inhibition of denovo D-Alanyl-D-alanine synthesis at 2 times MIC preincubated for 16 hrs followed L-Ala-[13C]-[3H] addition measured over 8 hrs by LC-MS/MS analysis	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID499899	Antitubercular activity against Mycobacterium tuberculosis H37Ra at 10 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID530769	Antimicrobial activity against beta-lactamase producing Staphylococcus aureus SH1000	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.
AID163253	Not Plasmodium species	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID733061	Antitubercular activity against Mycobacterium tuberculosis H37Rv by BacTiter-Gl Microbial Cell Viability assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
AID671443	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 15 to 20 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID571078	Antimicrobial activity against methicillin-resistant Staphylococcus aureus OC3726 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1765757	Antimycobacterial activity against Mycobacterium bovis BCG assessed as inhibition of bacterial growth at measured by microplate alamar blue assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Design and synthesis of novel 5-alkynyl pyrimidine nucleosides derivatives: Influence of C-6-substituent on antituberculosis activity.
AID428955	Antibacterial activity against LPS-deffective Escherichia coli OC2530 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID206401	antibacterial activity was reported as zones of inhibition in the disk diffusion assay using staphylococcus aureus	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Use of acetylacetone to prepare a prodrug of cycloserine.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1069174	Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by BacTiter-Glo assay	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Design, synthesis and evaluation of acridine and fused-quinoline derivatives as potential anti-tuberculosis agents.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474265	Antibacterial activity against Bacillus subtilis assessed as cell shape defects at 1 times MIC after 2 hrs in presence of methylsulfonyl methane by phase contrast microscopic analysis	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.
AID497739	Inhibition of IPTG-stimulated Escherichia coli K-12 ddlB at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID543950	Antibacterial activity against oxacillin, chloramphenicol-susceptible and erythromycin, tetracycline-resistant Staphylococcus aureus COL	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1501382	Inhibition of cell wall biosynthesis in Bacillus subtilis assessed as induction of large bulges formation at 37.5 ug/ml incubated for 2 hrs by FM-4-64 staining based assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Arylthiazole antibiotics targeting intracellular methicillin-resistant Staphylococcus aureus (MRSA) that interfere with bacterial cell wall synthesis.
AID774300	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate Alamar blue assay	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID428973	Bactericidal activity against LPS-deffective Escherichia coli OC2530 assessed as log reduction in CFU at 2 times MIC after 30 mins relative to control	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1072950	Inhibition of alanine racemase in Mycobacterium tuberculosis H37Rv assessed as remaining activity at MIC preincubated for 16 hrs followed by L-Ala-[13C]-[3H] addition measured over 8 hrs by LC-MS/MS analysis	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID571298	Bactericidal activity against LPS-deffective Escherichia coli OC2530 harboring pMurF plasmid at 2 times MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1474234	Antibacterial activity against tolC deficient Escherichia coli assessed as cell lysis at 125 ug/ml after 2 hrs in presence of sucrose by FM4-64/DAPI/SYTOX Green staining-based deconvolution microscopic analysis	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1765765	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of bacterial growth measured by microplate alamar blue assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Design and synthesis of novel 5-alkynyl pyrimidine nucleosides derivatives: Influence of C-6-substituent on antituberculosis activity.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID497885	Inhibition of IPTG-stimulated Escherichia coli K-12 tolC at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID671441	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 5 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID640487	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID1584835	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 to 24 hrs by microdilution assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
AID66241	Minimum inhibitory concentration compared to D-cycloserine, against Enterobacter cloacae 60.90	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1474233	Antibacterial activity against tolC deficient Escherichia coli assessed as formation of spheroplasts at 125 ug/ml after 30 mins in presence of sucrose by FM4-64/DAPI/SYTOX Green staining-based deconvolution microscopic analysis	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.
AID497723	Inhibition of IPTG-stimulated Escherichia coli K-12 yadR at 16 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1602937	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 5 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID1664573	Antitubercular activity against Mycobacterium tuberculosis H37Ra assessed as bacterial growth inhibition by MABA	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID497888	Inhibition of IPTG-stimulated Escherichia coli K-12 rpSR at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID571073	Antimicrobial activity against Escherichia coli OC9040 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID285160	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID306281	Antibacterial activity against acrAB deficient Escherichia coli 1411	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl).
AID428971	Antibacterial activity against mid-log culture of LPS-deffective Escherichia coli OC2530 assessed as cell lysis at 2 times MIC by optical density study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1713723	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities.
AID640473	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as growth inhibition at 15 to 20 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID114643	Compound was evaluated for elevation of cGMP in vivo through subcutaneous route	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1602928	Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID499891	Antitubercular activity against Mycobacterium bovis BCG at 10 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID499905	Antitubercular activity against Mycobacterium tuberculosis H37Ra infected in BALB/c mouse assessed as reduction of CFU counts in liver at 50 mg/kg, ip administered 5 days after infection for 25 days measured after 3 days last dose	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID571077	Antimicrobial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID497886	Inhibition of IPTG-stimulated Escherichia coli K-12 yjeE at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID64590	Minimum inhibitory concentration compared to D-cycloserine, against Escherichia coli UB 1005	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1584831	Inhibition of Enterococcus faecalis JH2-2 C-terminal 6His-tagged DdlB expressed in Escherichia coli LMG194 at 10 uM preincubated for 30 mins followed by substrate addition and measured after 20 mins by Biomol Green reagent assay relative to control	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
AID571079	Antimicrobial activity against methicillin-resistant Staphylococcus aureus OC2878 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID370562	Inhibition of D-alanine binding site of Escherichia coli D-alanine-D-alanine ligase B after 15 mins	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID55423	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Serratia marcescens 2840	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID145260	In vitro inhibition of [3H]glycine at NMDA receptor	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID574810	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID497907	Inhibition of IPTG-stimulated Escherichia coli K-12 yadR at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1602934	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 2 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID640331	Antimycobacterial activity against Mycobacterium bovis BCG assessed as growth inhibition at 10 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID1072958	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 0.25 to 16 times MIC after 7 days in presence of D-Alanine	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID560773	Antibacterial activity against Staphylococcus aureus TS2921 harboring ddlA Asp102Asn mutation after 20 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID428965	Antibacterial activity against methicillin-resistant Staphylococcus aureus OC2878 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1071102	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by broth microdilution assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID560776	Antibacterial activity against Staphylococcus aureus TS2921 harboring ddlA Asp102Asn mutation and coexpressing pSddlA which complements temperature sensitivity after 20 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID479438	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 50 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.
AID114661	Compound was evaluated for passive avoidance in vivo through intraperitoneal route	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID774293	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS-PMS assay	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID1209457	Unbound Cmax in human plasma	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID428959	Antibacterial activity against Escherichia coli OC9040 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID64588	Minimum inhibitory concentration compared to D-cycloserine, against Escherichia coli ATCC 9637	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID499888	Antitubercular activity against Mycobacterium tuberculosis H37Ra after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID560778	Antibacterial activity against Staphylococcus aureus RN4220 in fifth-instar silkworm larva infection model assessed as compound concentration per gram of larva causing reduction in survival after 48 hrs post dose at 27 degC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID340859	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID428972	Antibacterial activity against LPS-deffective Escherichia coli OC2530 assessed as cell lysis at 2 times MIC by colony forming assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID499904	Antitubercular activity against Mycobacterium tuberculosis H37Ra infected in BALB/c mouse assessed as reduction of CFU counts in lungs at 50 mg/kg, ip administered 5 days after infection for 25 days measured after 3 days last dose	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574808	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID640479	Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as growth inhibition at 10 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID205358	Minimum inhibitory concentration compared to D-cycloserine, against Serratia liquefaciens 52.56	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1584827	Antitubercular activity against Mycobacterium tuberculosis H37Rv	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
AID640474	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as growth inhibition at 5 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1474230	Antibacterial activity against tolC deficient Escherichia coli assessed as formation of misshapen cells at 125 ug/ml after 30 mins in presence of sucrose by FM4-64/DAPI/SYTOX Green staining-based deconvolution microscopic analysis	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.
AID163054	Minimum inhibitory concentration compared to D-cycloserine, against Proteus rettgeri 53.100	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID671438	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 100 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID55417	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from proteus vulgaris 2829	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID530534	Induction of PvraSr::lacZ gene expression in Staphylococcus aureus SH1000 at 150 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.
AID306280	Antibacterial activity against Escherichia coli 1411	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl).
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1072951	Inhibition of D-alanine-D-alanine ligase in Mycobacterium tuberculosis H37Rv assessed as inhibition of denovo D-Alanyl-D-alanine synthesis at MIC preincubated for 16 hrs followed by L-Ala-[13C]-[3H] addition measured over 8 hrs by LC-MS/MS analysis	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID571273	Antimicrobial activity against LPS-deffective Escherichia coli OC2530 assessed as cell aggregation at 0.5 times MIC by light microscopy relative to untreated control	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID340858	Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID125240	Minimum inhibitory concentration compared to D-cycloserine, against Moraxella glucidolytica 52.90	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1883681	Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Tuberculosis Drug Discovery: Challenges and New Horizons.
AID479638	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.
AID543952	Antibacterial activity against tetracycline-resistant Staphylococcus aureus COL-S carrying SAmecA plasmid	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1332980	Antitubercular activity against Mycobacterium tuberculosis H37Rv	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID430786	Partial agonist activity at glycine site of NMDA receptor in rat brain cortex membrane assessed as potentiation of [3H]Mk-801 binding by liquid scintillation counting relative to glycine in presence of antagonist 5,7-dichlorokynurenic acid	2009	Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16	Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
AID55424	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Staphylococcus aureus 2865	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID574809	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1072947	Competitive inhibition of D-alanine-D-alanine ligase in Mycobacterium tuberculosis H37Rv at MIC preincubated for 16 hrs followed by D-Ala-[2H] addition measured over 8 hrs by LC-MS/MS analysis	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1664591	Antitubercular activity against Mycobacterium tuberculosis H37Ra assessed as bacterial growth inhibition at 5 ug/ml by MABA relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID774292	Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate Alamar blue assay	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID640336	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as growth inhibition at 50 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID55283	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Escherichia coli 2891	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID571072	Antimicrobial activity against Escherichia coli OC2605 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID55418	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Pseudomonas aeruginosa 4279	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID571080	Antimicrobial activity against Staphylococcus aureus OC4172 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID671444	Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as inhibition of microbial growth at 0.5 to 100 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID55282	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from cloacae 2647	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID560774	Antibacterial activity against Staphylococcus aureus TS5337 harboring ddlA Pro178Ser mutation after 20 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID55415	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Klebsiella pneumoniae 4005	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID55617	Inhibition of DAla-DAla Ligase by the compound	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	(3-Amino-2-oxoalkyl)phosphonic acids and their analogues as novel inhibitors of D-alanine:D-alanine ligase.
AID774295	Antimycobacterial activity against kanamycin-resistant Mycobacterium tuberculosis ATCC 35827	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID640477	Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as growth inhibition at 100 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID285159	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID145253	In vitro maximal effect on [3H]-MK 801 binding to NMDA receptor as compared to a basal value of 100%	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
AID143225	Compound was evaluated for in vitro inhibition of [3H]TCP at NMDA receptor.	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID774297	Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID574807	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID285162	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID733054	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
AID428957	Inhibition of Escherichia coli OC2530 MurF assessed as ratio of UDP-MurNAc-tripeptide/UDP-MurNAc-pentapeptide level at 2 times MIC after 30 mins by HPLC	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID428974	Bactericidal activity against LPS-deffective Escherichia coli OC2530 assessed as log reduction in CFU at 2 times MIC after 3 hrs relative to control	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1664578	Antitubercular activity against Mycobacterium bovis BCG assessed as bacterial growth inhibition at 10 ug/ml by MABA relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID428960	Antibacterial activity against Escherichia coli ATCC 25922 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1584830	Inhibition of Enterococcus faecalis JH2-2 C-terminal 6His-tagged DdlB expressed in Escherichia coli LMG194 preincubated for 30 mins followed by substrate addition and measured after 20 mins by Biomol Green reagent assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID340860	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID571292	Inhibition of Staphylococcus aureus ATCC 29213 MurF assessed as UDP-MurNAc-pentapeptide product level at 2 times MIC by HPLC (Rvb = 1 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID640486	Antimycobacterial activity against Mycobacterium bovis BCG by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID571279	Antimicrobial activity against LPS-deffective Escherichia coli OC2530 harboring pASK plasmid by broth microdilution method in presence of chloramphenicol	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1071116	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 12.5 ug/ml after 7 days by microplate Alamar blue assay relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID346006	Inhibition of Escherichia coli DdlB	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening.
AID55284	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Escherichia coli DC2 4353	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID1183864	Bactericidal activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as reduction in inclusion forming unit compound treated at 5 to 25 uM for 1 hr prior infection measured 24 hrs post infection by immunofluorescence assay	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Design and synthesis of 3-isoxazolidone derivatives as new Chlamydia trachomatis inhibitors.
AID432804	Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL at 37 degC by population analysis method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Role of a sodium-dependent symporter homologue in the thermosensitivity of beta-lactam antibiotic resistance and cell wall composition in Staphylococcus aureus.
AID64591	Minimum inhibitory concentration required for the inhibition of Escherichia coli ATCC 9637	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1602933	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 1 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID55420	Minimum inhibitory concentration required for inhibition of D-alanyl-D-alanine ligase from Salmonella Typhimurium 3860	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphinic acid inhibitors of D-alanyl-D-alanine ligase.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID530525	Induction of Ppbp2::lacZ gene expression in Staphylococcus aureus SH1000 at 150 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.
AID640330	Antimycobacterial activity against Mycobacterium bovis BCG assessed as growth inhibition at 50 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID306282	Antibacterial activity against Staphylococcus aureus 8325-4	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl).
AID1467547	Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14	One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE.
AID640478	Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as growth inhibition at 50 ug/ml by microplate alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.
AID127622	The compound was tested for urinary recovery was assayed for its content for total cycloserine content employing the chemical assay in mouse	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Use of acetylacetone to prepare a prodrug of cycloserine.
AID1072955	Reduction in intracellular dipeptide D-alanyl-D-alanine pool size in Mycobacterium tuberculosis H37Rv up to 5 times MIC by filter-based mass spectrometry technique	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID497724	Inhibition of IPTG-stimulated Escherichia coli K-12 ddlB at 16 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1072956	Inhibition of D-alanine-D-alanine ligase in Mycobacterium tuberculosis H37Rv assessed as depletion in D-Alanyl-D-alanine level preincubated for 16 hrs measured post 24 hrs of compound washout	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID571294	Inhibition of LPS-deficient Escherichia coli OC2530 MurF harboring pASK plasmid assessed as UDP-MurNAc-tripeptide substrate level at 2 times MIC by HPLC (Rvb = 63 +/- 4 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID571295	Inhibition of LPS-deficient Escherichia coli OC2530 MurF harboring pMurF plasmid assessed as UDP-MurNAc-tripeptide substrate level at 2 times MIC by HPLC (Rvb = 220 +/- 65 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID499900	Antitubercular activity against Mycobacterium tuberculosis H37Ra at 5 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
AID163112	Minimum inhibitory concentration compared to D-cycloserine, against Pseudomonas aeruginosa A22	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?
AID1602936	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 4 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID571297	Inhibition of LPS-deficient Escherichia coli OC2530 MurF harboring pMurF plasmid assessed as UDP-MurNAc-pentapeptide product level at 2 times MIC by HPLC (Rvb = 2674 +/- 696 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID574811	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID571278	Antimicrobial activity against LPS-deffective Escherichia coli OC2530 harboring pMurF plasmid by broth microdilution method in presence of chloramphenicol	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1664590	Antitubercular activity against Mycobacterium tuberculosis H37Ra assessed as bacterial growth inhibition at 10 ug/ml by MABA relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1072957	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 0.25 to 16 times MIC after 7 days in presence of L-Alanine	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1664593	Antitubercular activity against Mycobacterium bovis BCG assessed as bacterial growth inhibition by alamar blue staining based assay	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1072952	Reduction in intracellular total Alanine pool size in Mycobacterium tuberculosis H37Rv at 0.25 to 5 times MIC by filter-based technique	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1428627	Antimycobacterial activity against Mycobacterium smegmatis MC2 155 after 3 days by broth macrodilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID571285	Inhibition of Staphylococcus aureus ATCC 29213 MurF assessed as UDP-MurNAc-tripeptide substrate level at 2 times MIC by HPLC (Rvb = 1 mAU)	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID560775	Antibacterial activity against Staphylococcus aureus TS10007 harboring ddlA Asp39Asn mutation after 20 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.
AID479633	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 25 ug/ml after 6 days by microplate alamar blue assay	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.
AID23504	Calculated partition coefficient (clogP) (Pomona)	1989	Journal of medicinal chemistry, Sep, Volume: 32, Issue:9	Evaluation and synthesis of aminohydroxyisoxazoles and pyrazoles as potential glycine agonists.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209455	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID428966	Antibacterial activity against Staphylococcus aureus OC4172 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID671439	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 50 ug/ml incubated for 6 days by MABA method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
AID428958	Antibacterial activity against Escherichia coli OC2605 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID1072945	Ratio of MIC for Mycobacterium tuberculosis H37Rv in presence of D-Alanine to MIC for Mycobacterium tuberculosis H37Rv	2013	ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12	Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID774294	Antimycobacterial activity against cycloserine-resistant Mycobacterium tuberculosis ATCC 35826	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.
AID1209456	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID55619	Compound was tested for its inhibitory activity against DAla-DAla Ligase	1989	Journal of medicinal chemistry, Jan, Volume: 32, Issue:1	Synthesis of an analogue of tabtoxinine as a potential inhibitor of D-alanine:D-alanine ligase (ADP forming).
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2003	The EMBO journal, Jun-16, Volume: 22, Issue:12	Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.
AID1811	Experimentally measured binding affinity data derived from PDB	2003	The EMBO journal, Jun-16, Volume: 22, Issue:12	Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1421 (59.68)	18.7374
1990's	183 (7.69)	18.2507
2000's	246 (10.33)	29.6817
2010's	446 (18.73)	24.3611
2020's	85 (3.57)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	192 (7.43%)	5.53%
Reviews	154 (5.96%)	6.00%
Case Studies	54 (2.09%)	4.05%
Observational	2 (0.08%)	0.25%
Other	2,181 (84.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (122)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effects of Mineralocorticoid Receptor Stimulation on Cognitive Bias and Social Cognition in Patients With Major Depression and Healthy Controls: What's the Role of NMDA Receptors? [NCT03062150]		232 participants (Actual)	Interventional	2016-09-27	Completed
The Effect of D-cycloserine on Fear Learning and Extinction [NCT01512316]		0 participants (Actual)	Interventional		Withdrawn(stopped due to Study was cancelled)
Investigating Methods to Enhance the Excitatory Effects of Transcranial Direct Stimulation (tDCS) [NCT01135953]		24 participants (Anticipated)	Interventional	2010-01-31	Completed
D-Cycloserine to Enhance Extinction to Alcohol Cues [NCT01362309]		37 participants (Actual)	Interventional	2010-11-30	Completed
The Clinical and Neural Response of Cocaine Addicts to Combination Treatment With a Cognitive Enhancer and Extinction-Based Psychotherapy [NCT01067846]		85 participants (Actual)	Interventional	2010-06-30	Completed
Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study [NCT02974010]	Phase 2	22 participants (Actual)	Interventional	2018-01-15	Completed
The Effect of Cyclosporine A Versus Tacrolimus on the Response to Antiviral Treatment After HCV Genotype -4 Recurrence in Recipients of Living Donor Liver Transplantation [NCT03665766]		126 participants (Actual)	Observational	2014-05-15	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
The Effect of NMDA Receptor Partial Agonist D-cycloserine on Emotional Processing, Stress and Memory in Healthy Volunteers [NCT03961464]		40 participants (Actual)	Interventional	2018-08-10	Completed
A Randomized Controlled Trial of Adjunctive D-Cycloserine to Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation in Fibromyalgia [NCT05395494]	Phase 2	90 participants (Anticipated)	Interventional	2022-08-29	Active, not recruiting
A Randomized Sham and Placebo-controlled Trial of Adjunctive D-cycloserine in Repetitive Transcranial Magnetic Stimulation for Obsessive Compulsive Disorder [NCT05177601]	Phase 2	81 participants (Anticipated)	Interventional	2021-11-26	Active, not recruiting
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739]		800 participants (Anticipated)	Observational [Patient Registry]	2018-07-01	Recruiting
A Six Month, Placebo-Controlled Trial of D-Cycloserine Co-Administered With Conventional Antipsychotics in Schizophrenia Patients [NCT00000371]	Phase 3	60 participants (Actual)	Interventional	1996-08-31	Completed
A Pilot Study Using Gradual Virtual Reality Exposure Therapy and D-Cycloserine (DCS) for Treatment of Combat Related Psychological Trauma in Burn Service Members [NCT00855153]		0 participants (Actual)	Interventional	2009-05-31	Withdrawn(stopped due to Investigator was not able to maintain IRB approval. Study never accrued subjects.)
A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers [NCT02128308]	Phase 1	16 participants (Actual)	Interventional	2013-11-30	Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
An Open Label Study of NRX-101 for Patients With Acute Complicated Urinary Tract Infection Including Pyelonephritis [NCT06128213]	Phase 2	13 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Randomized, Placebo-controlled, Crossover Trial of D-cycloserine Repetitive Transcranial Magnetic Stimulation Plasticity Enhancement in the Motor System of Individuals With Major Depressive Disorder. [NCT03511599]	Phase 1	12 participants (Actual)	Interventional	2018-09-03	Completed
Manipulating NMDA-dependent Learning to Alter Nocebo Effects: A Pharmacological fMRI Study on Pain [NCT04762836]		53 participants (Actual)	Interventional	2021-02-28	Completed
The Effect of Single Dose D-Cycloserine on Cognitive Outcome in Moderate TBI Patients [NCT01343862]	Phase 2	100 participants (Anticipated)	Interventional	2011-08-31	Not yet recruiting
A Randomized Placebo-controlled Trial of Adjunctive D-cycloserine in Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder [NCT03937596]	Phase 2	50 participants (Actual)	Interventional	2019-12-01	Completed
Lower Limb Function After Spinal Cord Injury [NCT02635893]	Phase 4	257 participants (Actual)	Interventional	2019-06-21	Completed
D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation [NCT00827281]	Phase 2	0 participants (Actual)	Interventional	2008-08-31	Withdrawn(stopped due to Study was not funded and pilot work proved impractical.)
D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain [NCT03535688]	Phase 2	244 participants (Anticipated)	Interventional	2018-03-30	Active, not recruiting
Motor Plasticity Enhancement of Spaced iTBS Trains: a Randomized, Placebo-controlled, Crossover Trial of D-cycloserine. [NCT05081986]	Phase 2	20 participants (Actual)	Interventional	2021-08-18	Completed
The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes [NCT00926900]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2009-03-31	Recruiting
The NMDA Receptor Co-agonist D-cycloserine Accelerates Associative Learning in the Human Hippocampal CA Region [NCT00980408]		120 participants (Actual)	Interventional	2008-06-30	Completed
The Effects of D-cycloserine on Neuroplasticity and Working Memory in Healthy Adults and Patients With Schizophrenia [NCT02769936]	Phase 1	110 participants (Actual)	Interventional	2013-11-30	Completed
Cycloserine in the Treatment of Sleep Apnea [NCT02735694]	Phase 1	18 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Analysis of initial sample shows negative results.)
Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers [NCT01907594]	Phase 2	0 participants (Actual)	Interventional	2013-08-31	Withdrawn(stopped due to Ran out of funding)
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine [NCT05994703]	Phase 2	25 participants (Anticipated)	Interventional	2023-10-20	Recruiting
A Cognitive Enhancer May Facilitate Behavioral Exposure Therapy for Veterans With PTSD [NCT00356278]	Phase 2/Phase 3	156 participants (Actual)	Interventional	2006-09-30	Completed
An Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) Augmented by D-Cycloserine as a Treatment for Depression. [NCT00869765]	Phase 2	5 participants (Actual)	Interventional	2009-04-30	Completed
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder [NCT00842309]	Early Phase 1	68 participants (Actual)	Interventional	2008-11-30	Completed
Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine [NCT00720759]	Phase 2	24 participants (Actual)	Interventional	2009-07-31	Completed
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder [NCT00790868]	Phase 2	180 participants (Actual)	Interventional	2008-04-30	Completed
Drug Discrimination in Methadone-Maintained Humans Study 2 [NCT00733239]	Phase 1	15 participants (Actual)	Interventional	2008-08-31	Completed
Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use [NCT00430573]	Phase 2	15 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to The investigators failed to recruit participants as originally projected.)
Open-Label Exploratory Investigation of D-Cycloserine Augmentation to Cognitive Behavioral Therapy With Exposure and Response Prevention for Adults and Adolescents Diagnosed With Obsessive Compulsive Disorder - A Feasibility Study [NCT01172873]		16 participants (Actual)	Interventional	2008-09-30	Completed
D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults [NCT01037101]		80 participants (Anticipated)	Interventional	2009-07-31	Recruiting
Food Exposure Therapy in Anorexia Nervosa [NCT00755820]		32 participants (Actual)	Observational	2008-01-31	Completed
Multimodal CET for Smoking Cessation Augmented With D-cycloserine [NCT04035603]	Phase 2	0 participants (Actual)	Interventional	2020-10-01	Withdrawn(stopped due to Never received funding)
Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder [NCT00674570]	Phase 4	111 participants (Actual)	Interventional	2009-01-13	Completed
Drug Discrimination in Methadone-Maintained Humans Study 3 [NCT01068847]	Phase 1	9 participants (Actual)	Interventional	2010-02-28	Completed
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia. [NCT00964041]	Phase 4	0 participants (Actual)	Interventional	2009-07-31	Withdrawn
Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia [NCT00742079]	Phase 4	21 participants (Actual)	Interventional	2006-09-30	Completed
A Phase III Study of D-Cycloserine in the Management of Paclitaxel-Induced Peripheral Neuropathic Pain in Breast Cancer Patients [NCT00301080]	Phase 3	7 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Funding for the study fell through.)
Cycloserine Enhancement of Extinction Learning [NCT01062932]	Phase 1	34 participants (Actual)	Interventional	2009-05-31	Completed
Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception [NCT01985750]	Early Phase 1	90 participants (Anticipated)	Interventional	2013-11-30	Recruiting
N-methyl-D-aspartate Receptor (NMDAR)-Based Pharmacotherapy With D-cycloserine for Treatment-resistant Major Depressive Disorder [NCT00408031]	Phase 2	26 participants (Actual)	Interventional	2007-01-31	Completed
Novel Pharmacological Strategies in Autism [NCT00198107]	Phase 3	81 participants (Actual)	Interventional	2005-09-30	Completed
Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain [NCT02385266]	Phase 4	24 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to The study was closed due to recruitment limitations)
A Randomized, Controlled, Multi-center Clinical Trial of Short Course Treatment for Newly Diagnosed Rifampicin Resistant Tuberculosis [NCT04545788]		200 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial [NCT01649895]	Phase 4	128 participants (Anticipated)	Interventional	2012-08-31	Completed
The Use of D-Cycloserine to Augment Intensive Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder [NCT01687140]	Phase 2	26 participants (Anticipated)	Interventional	2012-07-31	Recruiting
A Pharmacokinetic Study of Adjunctive D-cycloserine to Intermittent Theta Burst Stimulation in Major Depressive Disorder [NCT05731323]	Phase 1	12 participants (Actual)	Interventional	2022-10-12	Completed
The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial [NCT01680107]	Phase 3	33 participants (Actual)	Interventional	2012-10-31	Terminated
Drug Discrimination in Methadone-Maintained Humans Study 1 [NCT00593463]	Phase 1	40 participants (Anticipated)	Interventional	2006-09-30	Completed
Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled Na [NCT02656342]	Phase 4	163 participants (Actual)	Interventional	2015-11-30	Completed
Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes [NCT01102803]	Phase 3	40 participants (Actual)	Interventional	2010-04-30	Completed
A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia [NCT00963924]		54 participants (Actual)	Interventional	2009-08-31	Completed
D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression [NCT02772211]	Phase 4	60 participants (Anticipated)	Interventional	2016-06-30	Not yet recruiting
A Randomized Controlled Trial of D-Cycloserine in Autism [NCT00198120]	Phase 3	80 participants (Actual)	Interventional	2004-02-29	Completed
A Placebo Controlled Trial of Glycine Added to Clozapine in Schizophrenia [NCT00000372]	Phase 3	0 participants (Actual)	Interventional	1998-03-31	Withdrawn(stopped due to Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients with Schizophrenia, so the study was suspended.)
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects [NCT00635102]		57 participants (Actual)	Interventional	1997-10-31	Completed
D-Cycloserine and Virtual Reality Exposure Therapy Delivered on an iPad: Increasing Access to Treatment for Social Anxiety Disorder [NCT02933684]	Phase 2	0 participants (Actual)	Interventional	2015-01-01	Withdrawn(stopped due to Unable to access components necessary to be able to run the study.)
A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy [NCT00126282]		50 participants (Anticipated)	Interventional	2003-12-31	Completed
Medication Enhanced Rapid Therapy [NCT02099825]	Phase 1	15 participants (Actual)	Interventional	2014-01-13	Terminated(stopped due to COVID and staffing issues)
Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Panic Disorder [NCT00131339]		40 participants	Interventional	2004-11-30	Completed
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in [NCT00000796]		525 participants	Interventional		Completed
Cognitive Remediation With D-cycloserine to Improve Smoking Cessation Outcomes [NCT01399866]	Phase 3	150 participants (Actual)	Interventional	2011-05-31	Completed
Improving Learning-based Treatment of Cocaine Dependence With Medication [NCT01526538]	Phase 2	52 participants (Actual)	Interventional	2011-09-30	Completed
Effect of D-Cycloserine on Treatment of Social Phobia [NCT00128401]	Phase 2	48 participants (Actual)	Interventional	2005-08-31	Completed
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine [NCT01944423]	Early Phase 1	53 participants (Actual)	Interventional	2013-10-31	Completed
D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder [NCT00864123]	Phase 2	30 participants (Actual)	Interventional	2008-01-31	Completed
Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) [NCT00222235]	Phase 2/Phase 3	240 participants	Interventional	2000-01-31	Completed
D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression: A Multi-Site, Randomised, Placebo-Controlled Trial (COGENT) [NCT05591677]	Phase 2	180 participants (Anticipated)	Interventional	2023-04-21	Recruiting
D-cycloserine Enhancement of Exposure in Social Phobia [NCT00515879]	Phase 3	169 participants (Actual)	Interventional	2007-12-31	Completed
D-Cycloserine Facilitation of Cocaine - Cue Extinction [NCT00759473]	Phase 2	79 participants (Actual)	Interventional	2008-09-30	Completed
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals [NCT00455702]	Phase 4	38 participants (Actual)	Interventional	2004-07-31	Completed
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine [NCT02304432]	Early Phase 1	2 participants (Actual)	Interventional	2015-09-27	Completed
D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder [NCT00257361]	Phase 2	0 participants (Actual)	Interventional	2005-07-31	Withdrawn(stopped due to PI left the university)
Comparative Study of the Efficacy of a Cognitive-Behavioral Therapy for Post-Traumatic Stress Disorder With or Without D-Cycloserine [NCT00452231]	Phase 2/Phase 3	20 participants	Interventional	2007-02-28	Recruiting
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (TB-TRUST)-PLUS [NCT04717908]		89 participants (Actual)	Interventional	2021-01-20	Active, not recruiting
The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly [NCT01361633]	Phase 2	51 participants (Actual)	Interventional	2008-01-31	Completed
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls. [NCT01733030]		56 participants (Actual)	Observational	2013-01-31	Completed
NMDA Antagonists in Bipolar Depression [NCT01833897]	Phase 4	8 participants (Actual)	Interventional	2013-03-31	Completed
Improving Therapeutic Learning in Depression: Proof of Concept [NCT02376257]	Phase 2	36 participants (Actual)	Interventional	2014-09-16	Completed
A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy [NCT00182000]	Phase 3	33 participants (Actual)	Interventional	2003-11-30	Completed
A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders [NCT01086475]	Phase 3	68 participants (Actual)	Interventional	2010-03-31	Completed
Augmentation of Cognitive Training in Children With TBI With D-Cyloserine [NCT02312635]	Early Phase 1	30 participants (Anticipated)	Interventional	2012-12-31	Recruiting
D-Cycloserine in the Management of Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Pilot Study [NCT00125528]	Phase 2	41 participants (Actual)	Interventional	2012-07-31	Completed
Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer [NCT01352637]	Phase 3	192 participants (Actual)	Interventional	2011-05-31	Completed
Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo [NCT02582515]		20 participants (Actual)	Interventional	2015-10-31	Completed
Repetitive Acute Intermittent Hypoxia for Spinal Cord Repair [NCT03780829]	Early Phase 1	90 participants (Anticipated)	Interventional	2020-02-25	Recruiting
D-Cycloserine Enhancement of Exposure in Social Phobia [NCT00633984]	Phase 4	169 participants (Actual)	Interventional	2007-03-31	Completed
D-cycloserine: A Novel Treatment for Gulf War Illness [NCT02983734]	Phase 2	56 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Effect of D-cycloserine on Treatment of PTSD in Youth [NCT01157416]	Phase 2	33 participants (Actual)	Interventional	2010-06-30	Completed
Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics [NCT01450306]		20 participants (Actual)	Interventional	2010-07-31	Completed
Neurobiology of Opioid Dependence: 3 [NCT00000194]	Phase 2	0 participants (Actual)	Interventional	1993-01-31	Withdrawn
NMDA Receptors in Motor Learning in Humans [NCT02082912]	Phase 2	14 participants (Actual)	Interventional	2010-06-30	Completed
Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome [NCT02687165]		4 participants (Actual)	Interventional	2016-01-16	Terminated(stopped due to Slow recruitment due to strict inclusion/exclusion criteria)
Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder [NCT01928823]	Phase 2	73 participants (Actual)	Interventional	2011-11-30	Completed
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder [NCT02066792]	Early Phase 1	152 participants (Actual)	Interventional	2014-04-30	Completed
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions [NCT01981759]	Phase 4	58 participants (Actual)	Interventional	2014-02-28	Completed
Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD [NCT03216356]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2016-09-30	Withdrawn
A Randomized Placebo-controlled Trial of Adjunctive D-Cycloserine and Accelerated Intermittent Theta Burst Stimulation for Emerging Adults With Suicidal Ideation [NCT06121284]	Phase 2	60 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis [NCT06081361]	Phase 3	186 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia. [NCT00591825]	Phase 2	54 participants (Actual)	Interventional	2006-03-31	Completed
D-cycloserine Adjunctive Treatment for PTSD in Adolescents [NCT01157429]	Phase 2	24 participants (Actual)	Interventional	2010-06-30	Completed
Developing Memory Reconsolidation Blockers as Novel PTSD Treatments [NCT01490697]	Phase 4	34 participants (Actual)	Interventional	2009-03-31	Completed
A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD [NCT00371176]		26 participants (Actual)	Interventional	2006-10-31	Completed
Combined Exposure Therapy and D-Cycloserine vs. Placebo for Posttraumatic Stress Disorder [NCT00632632]		25 participants (Actual)	Interventional	2005-01-31	Completed
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers. [NCT00633256]		20 participants (Actual)	Interventional	2006-12-31	Completed
D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals [NCT00780442]	Phase 2	27 participants (Actual)	Interventional	2006-09-30	Completed
A Pragmatic Randomized Controlled Trial to Evaluate the Efficacy and Safety of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Patients With Multidrug-resistant Tuberculosis in China [NCT05306223]	Phase 4	212 participants (Anticipated)	Interventional	2022-05-10	Recruiting
A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder [NCT01934972]	Phase 3	30 participants (Actual)	Interventional	2013-03-31	Completed
1/2 D-cycloserine Augmentation of CBT for Pediatric OCD [NCT01411774]	Phase 3	142 participants (Actual)	Interventional	2011-06-30	Completed
Use of D-cycloserine to Facilitate Extinction of Food Aversion in Pediatric Populations [NCT01923896]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2013-03-31	Completed
2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD [NCT01404208]		206 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized, Placebo-controlled, Crossover Trial of Cycloserine Repetitive Transcranial Magnetic Stimulation Plasticity Enhancement in the Healthy Motor System. [NCT03432689]	Phase 1	12 participants (Actual)	Interventional	2018-08-06	Completed
D-cycloserine Augmented Treatment: Enhancing Extinction Learning in Youth With Tic Disorders [NCT04357951]	Early Phase 1	0 participants (Actual)	Interventional	2023-04-15	Withdrawn(stopped due to Low enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000371 (1) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS)
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00125528 (2) [back to overview]	McGill Pain Questionnaire (MPQ)
NCT00125528 (2) [back to overview]	Change in Numeric Rating Scale (NRS-11)
NCT00128401 (2) [back to overview]	Clinical Global Improvement (CGI-S) Scale
NCT00128401 (2) [back to overview]	Liebowitz Social Anxiety Scale (LSAS)
NCT00182000 (1) [back to overview]	Yale-Brown Obsessive Compulsive Scale (YBOCS)
NCT00198107 (10) [back to overview]	Mean Social Reciprocity Scale (SRS) Total Score, Week 8
NCT00198107 (10) [back to overview]	Mean Vineland Maladaptive Behavior Subscales Total Score, Week 8
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Stereotypy Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Autism Diagnostic Observation Schedule (ADOS) Social Affect and Restricted and Repetitive Behaviors Total Score, Week 8
NCT00198107 (10) [back to overview]	Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)
NCT00198107 (10) [back to overview]	Mean Post-baseline Score on a Modified Version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase
NCT00198107 (10) [back to overview]	Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Score, Parent Report, Double-blind Phase
NCT00356278 (10) [back to overview]	Clinician-Administered PTSD Scale (CAPS)
NCT00356278 (10) [back to overview]	Clinician-Administered PTSD Scale (CAPS)
NCT00356278 (10) [back to overview]	Clinician-Administered PTSD Scale (CAPS)
NCT00356278 (10) [back to overview]	Clinician-Administered PTSD Scale (CAPS)
NCT00356278 (10) [back to overview]	Clinician-Administered PTSD Scale (CAPS)
NCT00356278 (10) [back to overview]	PTSD Symptom Scale Self-Report
NCT00356278 (10) [back to overview]	PTSD Symptom Scale Self-Report
NCT00356278 (10) [back to overview]	PTSD Symptom Scale Self-Report
NCT00356278 (10) [back to overview]	PTSD Symptom Scale Self-Report
NCT00356278 (10) [back to overview]	PTSD Symptom Scale Self-Report
NCT00371176 (12) [back to overview]	Clinician Administered PTSD Scale-IV
NCT00371176 (12) [back to overview]	Clinician Administered PTSD Scale-IV
NCT00371176 (12) [back to overview]	PTSD Checklist
NCT00371176 (12) [back to overview]	PTSD Checklist
NCT00371176 (12) [back to overview]	PTSD Checklist
NCT00371176 (12) [back to overview]	PTSD Checklist
NCT00371176 (12) [back to overview]	Clinician Administered PTSD Scale-IV
NCT00371176 (12) [back to overview]	Beck Depression Inventory
NCT00371176 (12) [back to overview]	Beck Depression Inventory
NCT00371176 (12) [back to overview]	Beck Depression Inventory
NCT00371176 (12) [back to overview]	Beck Depression Inventory
NCT00371176 (12) [back to overview]	Clinician Administered PTSD Scale-IV
NCT00430573 (2) [back to overview]	Addiction Severity Index (ASI) Drug Use Composite Score
NCT00430573 (2) [back to overview]	Percentage of Positive Toxicology Swabs for Illicit Substances
NCT00455702 (2) [back to overview]	Treatment Effects on the Positive Syndrome Subscale of the PANSS
NCT00455702 (2) [back to overview]	Main Outcome Measure: The Change From Baseline to Week 8 on the SANS
NCT00515879 (6) [back to overview]	Social Phobia and Anxiety Inventory
NCT00515879 (6) [back to overview]	Range of Impaired Functioning Tool
NCT00515879 (6) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire
NCT00515879 (6) [back to overview]	Liebowitz Self-Rated Disability Scale
NCT00515879 (6) [back to overview]	Social Phobic Disorders Severity and Change Form
NCT00515879 (6) [back to overview]	Liebowitz Social Anxiety Scale (LSAS)
NCT00591825 (5) [back to overview]	Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)
NCT00591825 (5) [back to overview]	Cognitive Functioning Measured Using the Wisconsin Card Sorting Task
NCT00591825 (5) [back to overview]	Cognitive Functioning Measured Using the Iowa Gambling Test
NCT00591825 (5) [back to overview]	Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)
NCT00591825 (5) [back to overview]	fMRI Brain Activations During Symptom Provocation
NCT00632632 (3) [back to overview]	Structured Clinical Interview for DSM-IV - Major Depressive Disorder (SCID-MDD)
NCT00632632 (3) [back to overview]	Clinician Administered PTSD Scale(CAPS)
NCT00632632 (3) [back to overview]	Clinician Administered PTSD Scale(CAPS)
NCT00633256 (3) [back to overview]	Urinary Cotinine Level
NCT00633256 (3) [back to overview]	Cigarettes Smoked Per Day
NCT00633256 (3) [back to overview]	Cigarettes Smoked Per Day
NCT00633984 (2) [back to overview]	Liebowitz Social Anxiety Scale (LSAS)
NCT00633984 (2) [back to overview]	CGI - Clinical Global Impression of Improvement
NCT00635102 (45) [back to overview]	Visual Analog Scales of Similarity to Alcohol - Baseline
NCT00635102 (45) [back to overview]	Visual Analog Scales (VAS) - Baseline
NCT00635102 (45) [back to overview]	Visual Analog Scales (VAS) - 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Visual Analog Scales (VAS) - 60 Minutes
NCT00635102 (45) [back to overview]	Visual Analog Scales (VAS) - 30 Minutes
NCT00635102 (45) [back to overview]	Visual Analog Scales (VAS) - 120 Minutes
NCT00635102 (45) [back to overview]	Number of Drinks Felt Consumed at 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Number of Drinks Felt Consumed at 60 Minutes
NCT00635102 (45) [back to overview]	Number of Drinks Felt Consumed at 30 Minutes
NCT00635102 (45) [back to overview]	Number of Drinks Felt Consumed at 120 Minutes
NCT00635102 (45) [back to overview]	Hopkins Verbal Learning Task - Immediate Recall - 60 Minutes - Trial 3
NCT00635102 (45) [back to overview]	Hopkins Verbal Learning Task - Immediate Recall - 60 Minutes - Trial 2
NCT00635102 (45) [back to overview]	Hopkins Verbal Learning Task - Immediate Recall - 60 Minutes - Trial 1
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Desire to Drink - 120 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Desire to Drink - 60 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Desire to Drink - 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Desire to Drink- Baseline
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Desire to Drink: - 30 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Discomfort - 120 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Discomfort - 30 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Discomfort - 60 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Discomfort - 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Discomfort - Baseline
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Mood Improvement - 120 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Mood Improvement - 30 Minutes
NCT00635102 (45) [back to overview]	Hopkins Verbal Learning Task - Delay Recall - 90 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Mood Improvement - 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Mood Improvement - Baseline
NCT00635102 (45) [back to overview]	Visual Analog Scales of Similarity to Alcohol 30 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Reduced Control of Alcohol Use - 30 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Reduced Control of Alcohol Use - 60 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Reduced Control of Alcohol Use - 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Reduced Control of Alcohol Use - Baseline
NCT00635102 (45) [back to overview]	Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Biphasic Alcohol Effects Scale (BAES) Subscale Sedation - 120 Minutes
NCT00635102 (45) [back to overview]	Biphasic Alcohol Effects Scale (BAES) Subscale Sedation - 30 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Reduced Control of Alcohol Use - 120 Minutes
NCT00635102 (45) [back to overview]	Biphasic Alcohol Effects Scale (BAES) Subscale Sedation - Baseline
NCT00635102 (45) [back to overview]	Continuous Performance Task (CPT) - Distractibility A-Prime - 30 Minutes
NCT00635102 (45) [back to overview]	Alcohol Craving Scale (ACS) Subscale: Mood Improvement - 60 Minutes
NCT00635102 (45) [back to overview]	Visual Analog Scales of Similarity to Alcohol 60 Minutes Prior to Glycine Infusion
NCT00635102 (45) [back to overview]	Continuous Performance Task (CPT) - Vigilance - A-Prime Score 30 Minutes
NCT00635102 (45) [back to overview]	Visual Analog Scales of Similarity to Alcohol 60 Minutes
NCT00635102 (45) [back to overview]	Visual Analog Scales of Similarity to Alcohol 120 Minutes
NCT00635102 (45) [back to overview]	Biphasic Alcohol Effects Scale (BAES) Subscale Sedation - 60 Minutes
NCT00674570 (1) [back to overview]	Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS)
NCT00720759 (1) [back to overview]	Wolf Motor Function Test (Time)
NCT00742079 (5) [back to overview]	Change in Bead Task Score Measuring Probabilistic Reasoning
NCT00742079 (5) [back to overview]	Change in Alternative Beliefs Assessment
NCT00742079 (5) [back to overview]	Change in Beck Cognitive Insight Scale (BCIS)
NCT00742079 (5) [back to overview]	Change in the Maudsley Assessment of Delusions Scale
NCT00742079 (5) [back to overview]	Change in Psychotic Rating Scales (PSYRATS) Delusion Score
NCT00759473 (1) [back to overview]	Subjective Craving of Cocaine
NCT00780442 (1) [back to overview]	Cocaine Craving Scale
NCT00790868 (5) [back to overview]	Remission Status
NCT00790868 (5) [back to overview]	Role Functioning
NCT00790868 (5) [back to overview]	Quality of Life Ratings
NCT00790868 (5) [back to overview]	Depression Severity
NCT00790868 (5) [back to overview]	Panic Disorder Severity Scale (PDSS)
NCT00842309 (2) [back to overview]	Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)
NCT00842309 (2) [back to overview]	Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)
NCT00864123 (3) [back to overview]	Adverse Symptom Checklist (ASC; Goodman, 2005).
NCT00864123 (3) [back to overview]	Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997).
NCT00864123 (3) [back to overview]	Clinical Global Impression - Severity (CGI-S; National Institute of Mental Health, 1985). The CGI-S is a 7-point Clinician Rating of Severity of Psychopathology.
NCT00963924 (9) [back to overview]	Calgary Depression Scale for Schizophrenia (CDSS)
NCT00963924 (9) [back to overview]	Positive and Negative Syndrome Scale (PANSS)
NCT00963924 (9) [back to overview]	Heinrich Quality of Life Scale (QoL)
NCT00963924 (9) [back to overview]	Global Assessment of Functioning Scale (GAS)
NCT00963924 (9) [back to overview]	Side Effects Checklist (SEC)
NCT00963924 (9) [back to overview]	Scale for Assessment of Negative Symptoms (SANS)
NCT00963924 (9) [back to overview]	Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
NCT00963924 (9) [back to overview]	Clinical Global Impression (CGI)
NCT00963924 (9) [back to overview]	Auditory Discrimination Task: Interstimulus Interval (ISI)
NCT01067846 (2) [back to overview]	Drug Abstinence During Treatment and at Follow up Visits
NCT01067846 (2) [back to overview]	Treatment Retention - Number of Visits During Treatment
NCT01086475 (3) [back to overview]	Social Responsiveness Scale (SRS) Change
NCT01086475 (3) [back to overview]	Social Responsiveness Scale (SRS) at Follow-Up
NCT01086475 (3) [back to overview]	Clinical Global Impressions Improvement Scale Responder Analysis
NCT01102803 (4) [back to overview]	Clinical Global Improvement Scale (CGI)
NCT01102803 (4) [back to overview]	Attitudes Towards Heights Questionnaire (ATHQ)
NCT01102803 (4) [back to overview]	Acrophobia Questionnaire With Avoidance (AAVQ)
NCT01102803 (4) [back to overview]	Behavioral Avoidance Test (BAT)
NCT01157416 (1) [back to overview]	Child PTSD Symptom Scale (CPSS)
NCT01157429 (1) [back to overview]	Child PTSD Symptom Scale (CPSS)
NCT01172873 (3) [back to overview]	Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS) for Adolescents
NCT01172873 (3) [back to overview]	Beck Depression Inventory (BDI)
NCT01172873 (3) [back to overview]	Multidimensional Anxiety Scale for Children (MASC)
NCT01352637 (1) [back to overview]	CAPS-IV at the End of Treatment
NCT01361633 (7) [back to overview]	Wisconsin Card Sort Test
NCT01361633 (7) [back to overview]	California Verbal Learning Test-II (CLVT-II)
NCT01361633 (7) [back to overview]	Stroop
NCT01361633 (7) [back to overview]	Controlled Oral Word Association Test
NCT01361633 (7) [back to overview]	Implicit Memory Task
NCT01361633 (7) [back to overview]	Trails B
NCT01361633 (7) [back to overview]	Continuous Performance Test
NCT01399866 (6) [back to overview]	Effect of D-cycloserine + Cue-exposure Treatment on Electromyogram
NCT01399866 (6) [back to overview]	Effect of D-cycloserine + Cue-exposure Treatment on Heart Rate
NCT01399866 (6) [back to overview]	Effect of D-cycloserine + Cue-exposure Treatment on Skin Conductance
NCT01399866 (6) [back to overview]	Effect of D-cycloserine + Cue-exposure Treatment on Craving
NCT01399866 (6) [back to overview]	Effect of D-cycloserine + Cue-exposure Treatment on Continuous Abstinence From Tobacco Smoking.
NCT01399866 (6) [back to overview]	Effect of D-cycloserine + Cue-exposure Treatment on Attentional Bias Toward Smoking Cuesmeasured With the Emotional Stroop Task
NCT01404208 (2) [back to overview]	Clinical Global Impression-Severity (CGI-Severity)
NCT01404208 (2) [back to overview]	Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT01411774 (2) [back to overview]	Children's Yale-Brown Obsessive-Compulsive Scale.
NCT01411774 (2) [back to overview]	Clinical Global Impression-Severity
NCT01450306 (3) [back to overview]	Clinician's Global Impression (CGI)-Improvement
NCT01450306 (3) [back to overview]	Clinician's Global Impression (CGI)-Severity
NCT01450306 (3) [back to overview]	Snake Questionnaire (SNAQ)
NCT01490697 (2) [back to overview]	Physiological Posttraumatic Stress Disorder (PTSD) Probability as Determined From Psychophysiologic Responses to Traumatic Recollection
NCT01490697 (2) [back to overview]	Change From Baseline in the Impact of Event Scale-Revised (IES-R) Total Score
NCT01526538 (3) [back to overview]	Medication Side-effects
NCT01526538 (3) [back to overview]	Learning Task by Itami and Uno
NCT01526538 (3) [back to overview]	Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml)
NCT01833897 (5) [back to overview]	Loss of Motivated Behavior HAM-D Factor
NCT01833897 (5) [back to overview]	Hamilton Depression Rating Scale (HAM-D)
NCT01833897 (5) [back to overview]	Hamilton Anxiety Scale
NCT01833897 (5) [back to overview]	HAM-D Suicide Item
NCT01833897 (5) [back to overview]	Beck's Depression Inventory
NCT01923896 (4) [back to overview]	Disruptions
NCT01923896 (4) [back to overview]	Disruptions
NCT01923896 (4) [back to overview]	Rapid Swallowing
NCT01923896 (4) [back to overview]	Rapid Swallowing
NCT01934972 (12) [back to overview]	Frequency of Side Effects During Study Participation
NCT01934972 (12) [back to overview]	Change From Baseline in Cognitive Functioning
NCT01934972 (12) [back to overview]	Change From Baseline in Depressive Symptomatology
NCT01934972 (12) [back to overview]	Change From Baseline in Functional Capacity
NCT01934972 (12) [back to overview]	Change From Baseline in Health-related Quality of Life
NCT01934972 (12) [back to overview]	Change From Baseline in Manic Symptomatology
NCT01934972 (12) [back to overview]	Change From Baseline in Medication Adherence
NCT01934972 (12) [back to overview]	Change From Baseline in Metacognition
NCT01934972 (12) [back to overview]	Change From Baseline in Social Functioning
NCT01934972 (12) [back to overview]	Change From Baseline in Stage of Recovery
NCT01934972 (12) [back to overview]	Change in Instrinsic Motivation From Baseline
NCT01934972 (12) [back to overview]	Change From Baseline in Quality of Life
NCT01944423 (3) [back to overview]	Anxiety Sensitivity Mechanistic Target
NCT01944423 (3) [back to overview]	Panic Symptoms Mechanistic Target
NCT01944423 (3) [back to overview]	Smoking Abstinence
NCT01981759 (3) [back to overview]	Change in Psychotic Symptoms Rating Scale-Delusions (PSYRATS-D)
NCT01981759 (3) [back to overview]	Change in Alternate Beliefs Exercise (ABE)
NCT01981759 (3) [back to overview]	Change in Logical Memory Test-WMS-III
NCT02066792 (1) [back to overview]	Social Anxiety Symptom Severity
NCT02082912 (5) [back to overview]	Number of Blocks Moved During the Box and Block Test (BBT) of Affected Arm
NCT02082912 (5) [back to overview]	Center for Epidemiologic Studies Depression (CES-D) Scale Score
NCT02082912 (5) [back to overview]	Display Enhanced Testing for Concussions and Mild Traumatic Brain Injury (mTBI) (DETECT) System Score
NCT02082912 (5) [back to overview]	Percentage of Stroke Impact Scale (SIS) Categories Meeting Change Criteria
NCT02082912 (5) [back to overview]	Grip Strength of Affected Hand
NCT02304432 (16) [back to overview]	Neurocognitive Function
NCT02304432 (16) [back to overview]	Clinical Global Impression (CGI) Severity Scores
NCT02304432 (16) [back to overview]	Brief Psychiatric Rating Scale (BPRS) Scores
NCT02304432 (16) [back to overview]	Brief Psychiatric Rating Scale (BPRS) Scores
NCT02304432 (16) [back to overview]	Brain Glycine/CR Ratio
NCT02304432 (16) [back to overview]	Auditory Evoked Potentials in Latency (Msec)
NCT02304432 (16) [back to overview]	Auditory Evoked Potentials in Amplitude (Degrees Measured in Microvolts)
NCT02304432 (16) [back to overview]	Auditory Evoked Potentials - P50 Ratio (P50 S2/S1) (Amplitude)
NCT02304432 (16) [back to overview]	Auditory Evoked Potentials in Gamma Oscillations (the Power Spectrum is Measured in Microvolts Squared)
NCT02304432 (16) [back to overview]	Depression Symptom Scores
NCT02304432 (16) [back to overview]	Depression Symptom Scores
NCT02304432 (16) [back to overview]	Mania Symptom Scores
NCT02304432 (16) [back to overview]	Clinical Global Impression (CGI) Severity Scores
NCT02304432 (16) [back to overview]	Mania Symptom Scores
NCT02304432 (16) [back to overview]	Positive and Negative Symptom Scores
NCT02304432 (16) [back to overview]	Positive and Negative Symptom Scores
NCT02376257 (8) [back to overview]	Recall of Cognitive Therapy Content
NCT02376257 (8) [back to overview]	1 Week Delayed Recall of Emotional Story Items
NCT02376257 (8) [back to overview]	Digits Backward
NCT02376257 (8) [back to overview]	1 Week Delayed Recall Logical Memory
NCT02376257 (8) [back to overview]	Immediate Memory Measured by the Hopkins Verbal Learning Task
NCT02376257 (8) [back to overview]	Immediate Recall of Emotional Story Items
NCT02376257 (8) [back to overview]	Skills of Cognitive Therapy
NCT02376257 (8) [back to overview]	Logical Memory Immediate Recall
NCT02385266 (1) [back to overview]	Visual Analog Scale (VAS)
NCT02582515 (1) [back to overview]	Hopkins Motor/Vocal Tic Scale (HM/VTS)
NCT02974010 (1) [back to overview]	BDM Score (BISS-derived MADRS) Change From Baseline at Day 42

Scale for the Assessment of Negative Symptoms (SANS)

The slope of SANS total score from baseline to week 8 in the treatment and placebo groups on the scale for the assessment of negative symptoms (SANS) total score. Total SANS scores range from 0-100. The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each scale, the higher the score the more prominent the negative symptoms were. The slopes were obtained by plotting the group SANS total score mean for treatment vs. placebo on Baseline, Week 4, and Week 8 and performing a random slopes model. (NCT00000371)
Timeframe: Baseline, Week 4, Week 8

Intervention	units on a scale/weeks (Mean)
D-Cycloserine	-.46
Placebo	-.41

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	mg/L (Median)
	2nd Trimester	3rd Trimester	Postpartum
ATV/COBI 300/150 mg q.d.	0.21	0.21	0.61
ATV/RTV Arm 1: 300/100mg q.d.	2.0	0.7	1.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.49	0.71	0.90
DRV/COBI 800/150 mg q.d.	0.33	0.27	1.43
DRV/RTV 800/100mg q.d.	0.99	1.17	2.78
DTG 50mg q.d.	0.73	0.93	1.28
EFV 600 mg q.d. (Outside THA)	1.49	1.48	1.94
EVG/COBI 150/150mg q.d.	0.0258	0.0487	0.3771
TAF 10mg q.d. w/COBI	0.00195	0.00195	0.00195
TAF 25mg q.d.	0.00195	0.00195	0.00195
TAF 25mg q.d. w/COBI or RTV Boosting	0.00195	0.00195	0.00195
TFV 300mg q.d.	0.039	0.054	0.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.	0.3	0.5	0.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.44	0.57	1.26

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	pg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG	604
LPV/RTV 400/100 b.i.d. With ENG	428
EFV 600mg q.d. With ENG	125

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	85.3
VRE Therapy and Alprazolam	88
VRE Therapy and Placebo	82.6

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	48.0
VRE Therapy and Alprazolam	57.2
VRE Therapy and Placebo	48.4

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	60.3
VRE Therapy and Alprazolam	66.8
VRE Therapy and Placebo	51.5

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	56.0
VRE Therapy and Alprazolam	63.4
VRE Therapy and Placebo	46.9

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	65.9
VRE Therapy and Alprazolam	69.6
VRE Therapy and Placebo	63.8

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	32.9
VRE Therapy and Alprazolam	32.4
VRE Therapy and Placebo	32.4

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	22.6
VRE Therapy and Alprazolam	24.2
VRE Therapy and Placebo	21.7

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	25.2
VRE Therapy and Alprazolam	26.1
VRE Therapy and Placebo	21.4

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	24.1
VRE Therapy and Alprazolam	26.3
VRE Therapy and Placebo	20.0

Intervention	units on a scale (Mean)
VRE Therapy and D-cycloserine	27.1
VRE Therapy and Alprazolam	25.6
VRE Therapy and Placebo	24.2

Intervention	units on a scale (Mean)
	Baseline	Mid-Treatment (week 6)	Endpoint of Treatment (week 12)	Follow-Up 1 (week 15)	Follow-Up 2 (week 18)
Randomized Participants That Completed Baseline ASI	0.27	0.19	0.21	0.30	0.18

Intervention	percentage of positive toxicology swabs (Mean)
	Baseline Period	Treatment Period (week12)	Follow-up Period (week 18)
All Randomized Participants	80.0	65.7	59.6

Intervention	score on a scale (Mean)
	3 Months	6 Months	9 Months
D-cycloserine-augmented CBT	71.08	69.64	67.67
Placebo-augmented CBT	73.74	71.97	67.74

cycloserine

Description

Cross-References

Synonyms (232)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (4)

Protein Targets (54)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (32)

Molecular Functions (16)

Ceullar Components (16)

Bioassays (346)

Research

Studies (2,381)

Market Indicators

Research Demand Index: 62.03

Study Types

Clinical Trials (122)

Trial Overview

Trial Outcomes

Scale for the Assessment of Negative Symptoms (SANS)

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Plasma Concentration for Contraceptives

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

McGill Pain Questionnaire (MPQ)

Change in Numeric Rating Scale (NRS-11)

Clinical Global Improvement (CGI-S) Scale

Liebowitz Social Anxiety Scale (LSAS)

Yale-Brown Obsessive Compulsive Scale (YBOCS)

Mean Social Reciprocity Scale (SRS) Total Score, Week 8

Mean Vineland Maladaptive Behavior Subscales Total Score, Week 8

Mean Post-baseline Aberrant Behavior Checklist Stereotypy Score, Parent Report, Double-blind Phase

Mean Autism Diagnostic Observation Schedule (ADOS) Social Affect and Restricted and Repetitive Behaviors Total Score, Week 8

Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)

Mean Post-baseline Score on a Modified Version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Score, Parent Report, Double-blind Phase

Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Score, Parent Report, Double-blind Phase

Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase

Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Score, Parent Report, Double-blind Phase

Clinician-Administered PTSD Scale (CAPS)

Clinician-Administered PTSD Scale (CAPS)

Clinician-Administered PTSD Scale (CAPS)

Clinician-Administered PTSD Scale (CAPS)

Clinician-Administered PTSD Scale (CAPS)

PTSD Symptom Scale Self-Report

Intervention	units on a scale (Mean)
	Logical Memory 1	Logical Memory 2	Faces 1	Faces 2
Non-Phobic Control - DCS	49	32.46	41.85	41.62
Non-Phobic Control - Placebo	51.93	34.36	40.43	41.93
Spider-phobic DCS	52.93	35.43	42.07	42.07
Spider-phobic Placebo	52.69	34.85	41	41.62

Intervention	units on a scale (Mean)
Non-Phobic Control - Placebo	13.29
Non-Phobic Control - DCS	13.62
Spider-phobic Placebo	18.23
Spider-phobic DCS	15.67

Intervention	units on a scale (Mean)
Non-Phobic Control - Placebo	44.29
Non-Phobic Control - DCS	32.62
Spider-phobic Placebo	28.58
Spider-phobic DCS	21.85

Intervention	units on a scale (Mean)
	Organization	Copy	Immediate	Delay
Non-Phobic Control - DCS	4.92	34.46	24.77	23.35
Non-Phobic Control - Placebo	4.93	34.68	26.54	26.08
Spider-phobic DCS	4.14	34.50	26.14	25.64
Spider-phobic Placebo	3.69	34.46	26.17	26.13

Intervention	percent signal change (Mean)
	Left Insula Spider	Left Insula Butterfly	Right Insula Spider	Right Insula Butterfly	mid dorsal ACC Spider	mid dorsal ACC Butterfly	Left dlPFC Spider	Left dlPFC Butterfly	Right dlPFC Spider	Right dlPFC Butterfly	Left amygdala Spider	Left amygdala Butterfly	Right amygdala Spider	Right amygdala Butterfly	Left hippocampus Spider	Left hippocampus Butterfly	Right hippocampus Spider	Right hippocampus Butterfly
DCS Control	.157	.021	.174	.109	.402	.053	.122	.076	.521	.431	.202	.149	.155	.181	.196	.065	.310	.219
DCS Phobic	.200	.012	.107	.017	.242	.022	.250	.031	.384	.150	.322	.127	.241	.082	.101	.010	.113	.017
Placebo Control	.036	.079	.020	.017	.071	-.059	.278	.075	.038	.110	.427	.098	.133	-.017	.131	.086	.361	.329
Placebo Phobic	-.013	.092	-.004	.133	.073	.085	.019	.035	.301	.249	.534	.254	.183	.203	.185	.204	.075	.155

Intervention	units on a scale (Mean)
Cognitive Behavioral Group Therapy + 50mg D-Cycloserine	39.19
Cognitive Behavioral Group Therapy + 50mg Placebo	42.44

Intervention	units on a scale (Mean)
Cognitive Behavioral Group Therapy + 50mg D-Cycloserine	2.68
Cognitive Behavioral Group Therapy + 50mg Placebo	2.95

Intervention	units on a scale (Mean)
	Glycine / Cycloserine	Glycine / Placebo	Placebo / Cycloserine	Placebo / Placebo
Alcoholic Subjects	0.18	0.25	0.10	0.24
Healthy Subjects	0.05	0.04	0.04	0

Intervention	proportion of max SCR (µS) (Mean)
	Fear Conditioning: Beginning	Fear Conditioning: End	Fear Extinction: Beginning	Fear Extinction: End	Extinction Retention
Arm 1: Hydrocortisone	.0325522	.1233174	.0298132	.0013351	-.0101856
Arm 2: D-Cycloserine	.0245775	.1024914	.0674658	-.026853	-.0248148
Arm 3: Placebo	-.0181339	.1276977	.1104578	.0854075	.0985292

Intervention	units on a scale (Mean)
	Composite Score	Self-Certainty Score	Self-Reflectiveness Score
D-cycloserine	-0.26	0.11	-0.16
Placebo	0.44	-0.56	-0.11